<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Med</journal-id>
<journal-title-group>
<journal-title>Genetics in Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1098-3600</issn>
<issn pub-type="epub">1530-0366</issn>
<publisher>
<publisher-name>Nature Publishing Group US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32284538</article-id>
<article-id pub-id-type="pmc">7332419</article-id>
<article-id pub-id-type="publisher-id">779</article-id>
<article-id pub-id-type="doi">10.1038/s41436-020-0779-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>X-linked diseases: susceptible females</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2932-5226</contrib-id>
<name>
<surname>Migeon</surname>
<given-names>Barbara R.</given-names>
</name>
<degrees>MD</degrees>
<address>
<email>bmigeon@jhmi.edu</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Departments of Genetic Medicine and Pediatrics, </institution><institution>The Johns Hopkins Medical Institutions, </institution></institution-wrap>Baltimore, MD USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>14</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>14</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2020</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>1156</fpage>
<lpage>1174</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>3</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The role of X-inactivation is often ignored as a prime cause of sex differences in disease. Yet, the way males and females express their X-linked genes has a major role in the dissimilar phenotypes that underlie many rare and common disorders, such as intellectual deficiency, epilepsy, congenital abnormalities, and diseases of the heart, blood, skin, muscle, and bones. Summarized here are many examples of the different presentations in males and females. Other data include reasons why women are often protected from the deleterious variants carried on their X chromosome, and the factors that render women susceptible in some instances.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© American College of Medical Genetics and Genomics 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>INTRODUCTION</title>
<p id="Par2">Sex differences in human disease are usually attributed to sex specific life experiences, and sex hormones that influence the function of susceptible genes throughout the genome.<sup><xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref></sup> Such factors do account for some dissimilarities. However, a major cause of sex-determined expression of disease has to do with differences in how males and females transcribe their gene-rich human X chromosomes, which is often underappreciated as a cause of sex differences in disease.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> Males are the usual ones affected by X-linked pathogenic variants.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> Females are biologically superior; a female usually has no disease, or much less severe disease than the male with the same variant, unless she is homozygous for the deleterious allele, or it is lethal for males.</p>
<p id="Par3">The X chromosome carries 867 known protein coding genes.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> Clearly, pathogenic variants that induce complete loss of function may be lethal to fetuses of both sexes; however, a number of these pathogenic variants—less severe, or occurring in less-essential genes—cause at least 533 X-linked diseases<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> that affect males more severely.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> Rather than influencing sexual development, most of these genes play a role in nonreproductive human tissues, including brain, bone, blood, ears, heart, liver, kidney, retina, skin, and teeth.</p>
<p id="Par4">Table <xref ref-type="table" rid="Tab1">1</xref> provides data about a substantial number of X-linked disorders obtained in large part from OMIM<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> that confirm the lesser susceptibility of females. The table is not all-inclusive, but it provides enough data to show the greater severity of these diseases in males, and to illustrate why some, but not all, females with the same X-linked deleterious allele are protected from its effects. This paper is motivated by the question: When so many women are protected from manifesting severe X-linked diseases, why are some of them susceptible?<table-wrap id="Tab1"><label>Table. 1</label><caption><p>Effect of X-inactivation (XI) on phenotype and cell selection in X-linked disorders.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>X-linked disease</th><th>X Map</th><th>Gene</th><th>OMIM</th><th>Phenotype: males</th><th>Phenotype: females</th><th>Cell selection</th><th>Tissue</th><th>XI skewing assay</th></tr></thead><tbody><tr><td><p><bold>Aarskog–Scott syndrome</bold></p><p><bold>allelic with XLMR 16</bold></p></td><td><p><bold>Xp11.2</bold></p><p><bold>54,445,453</bold></p></td><td><p><bold><italic>FGD1</italic></bold></p><p><bold>premature termination;</bold></p><p><bold>truncation</bold></p></td><td>305400</td><td>Faciogenital dysplasia (ocular hypertelorism, shawl scrotum) with attention deficit hyperactivity, also XLID</td><td><p>Subtle features as widows peak or short stature</p><p>Skewing toward mutant increases severity (i.e., translocation)</p></td><td>ND</td><td></td><td></td></tr><tr><td><bold>XLMR 16</bold></td><td><p><bold>Xp11.22</bold></p><p><bold>54,445,453</bold></p></td><td><p><bold><italic>FGD1</italic></bold></p><p><bold>missense</bold></p></td><td>305400</td><td>ID only</td><td>No affected females</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>Acrogigantism X-LAG</bold></p><p><bold>allelic with X-linked immunodeficiency with hyper IGM</bold></p></td><td><p><bold>Xq26.3</bold></p><p><bold>136,648,176</bold></p></td><td><p><bold><italic>CD40LG</italic></bold></p><p>300386</p><p><bold>microduplication</bold></p></td><td>300942</td><td>Microduplications: only mosaic males are cited, so may be lethal in most males; mosaic males have acrogigantism, but no immunodeficiency</td><td><p>Females are like mosaic males; acrogiantism, but no immunodeficiency</p><p>Elevated growth hormone &amp; prolactin</p></td><td><p>Microduplications have random XI</p><p>Affected females may not be skewed until older age</p></td><td>Lymphocytes</td><td><italic>AR</italic></td></tr><tr><td><bold>Immunodeficiency with hyper IGM (HIGM) Immunodeficiency 3</bold></td><td><p><bold>Xq26.3</bold></p><p><bold>136,648,176</bold></p></td><td><p><bold><italic>CD40LG</italic></bold>
<bold>(CD40 ligand on T cells)</bold></p><p><bold>variants</bold></p></td><td>308230</td><td>Decreased IgG, IgA, &amp; IgE; susceptibility to opportunistic bacterial diseases, leading to liver disease; most have severe infections &amp; shortened life spans</td><td>Heterozygotes have normal levels of IgG, IgA, IgM, &amp; IgE</td><td>Not convincing as reports conflict; it seems that half normal is enough to protect females</td><td>T and B cells &amp; fibroblasts</td><td></td></tr><tr><td>Adrenoleukodystrophy</td><td><p>Xq28</p><p>153,724,850</p></td><td><italic>ABCD1</italic></td><td>300100</td><td>Demyelinization of brain, spinal cord, &amp; adrenals. Often death in first decade</td><td>Adrenomyeloneuropathy; spastic paraplegia with age</td><td>Yes, gradual. Favors mutant allele</td><td>WBC, RBC, skin fibroblasts clones</td><td><italic>G6PD</italic> &amp; fatty acids</td></tr><tr><td>Alport syndrome</td><td><p>Xq22.3</p><p>108,439,837</p></td><td><italic>COL4A5</italic></td><td>301050</td><td>End stage renal disease; hearing loss; ocular malformations</td><td><p>Milder renal disease</p><p>Severity related to skewing</p></td><td>Severity related to skewing toward mutant allele</td><td><p>WBC</p><p>Kidney glomeruli</p></td><td><p><italic>HPRT</italic> &amp; <italic>PGK.</italic></p><p><italic>COL45A</italic> Immunolabel</p></td></tr><tr><td>Amelogenesis imperfecta</td><td><p>Xp22.2</p><p>11,293,412</p></td><td><italic>AMELX</italic></td><td>301200</td><td><p>Hypoplastic amelogenesis imperfecta;</p><p>Mottled teeth (fluoride independent); Homogeneous pattern of abnormality</p><p>AMELY expressed at 10% activity of AMELX</p></td><td>Vertically grooved teeth; variable depending on skew of XI</td><td>One homozygous female was affected like her hemizygous father, and more severe than her heterozygous mother; mother 25% skewed toward mutant, reflected in degree of grooving</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Androgen insensitivity</bold></td><td><p><bold>Xq12</bold></p><p><bold>67,544,020</bold></p></td><td><p><bold>AR</bold></p><p><bold>loss of function hypomorphic</bold></p></td><td>300068</td><td>Feminization or hypospadias and micropenis</td><td>No affected females</td><td><p>ND</p><p>Not severe (two clonal populations, but lower binding in heterozygotes)</p></td><td>Skin fibroblast clones, both normal and mutant present</td><td>Androgen binding</td></tr><tr><td><bold>Kennedy spinal bulbar &amp; muscular atrophy</bold></td><td><p><bold>Xq12</bold></p><p><bold>67,544,020</bold></p></td><td><p><bold>AR</bold></p><p><bold>trinucleotide repeat expansion</bold></p></td><td>313200</td><td><p>36–62 repeats in males; onset: 3rd–5th decade;</p><p>slowly progressive muscle atrophy; progressive decrease in sperm production</p></td><td>Affected, if homozygous, but less affected because of higher androgens in males; heterozygotes usually normal, but some muscle cramps</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>ATRX syndrome</bold></p><p><bold>ɑ-thalessemia/ID syndrome</bold></p></td><td><p><bold>Xq21.1</bold></p><p><bold>77,504,877</bold></p></td><td><p><bold><italic>ATRX</italic></bold></p><p><bold>300032</bold></p></td><td>301040</td><td><p>ID, thalassemia,</p><p>genital abnormalities attributable to variants in PHD domain</p></td><td><p>Hemoglobin H inclusions</p><p>Mild retardation, usually unaffected</p></td><td>Yes, severe toward wild type allele</td><td>WBC, buccal smear</td><td><italic>AR</italic></td></tr><tr><td>ɑ<bold>-thalessemia Myelodysplastic syndrome</bold></td><td><p><bold>Xq21.1</bold></p><p><bold>77,504,877</bold></p></td><td><bold><italic>ATRX</italic></bold></td><td>300448</td><td>Severe variant reducing activity to 3–4% normal</td><td>No affected females</td><td>Yes, severe toward wild type allele</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>MR-hypotonic facies syndrome</bold></td><td><p><bold>Xq21.1</bold></p><p><bold>77,504,877</bold></p></td><td><bold><italic>ATRX</italic></bold></td><td>309580</td><td><p>Not so severe variants or those in the helical domain</p><p>No genital abnormalities</p></td><td>No affected females</td><td>Yes, severe toward wild type allele</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Barth syndrome</td><td><p>Xq28</p><p>154,411,517</p></td><td><italic>TAZ</italic></td><td>302060</td><td><p>Idiopathic cardiomyopathy</p><p>Methylglutaconic</p><p>aciduria</p><p>Abnormal mitochondria</p><p>Death in childhood</p></td><td>No affected females</td><td>Yes, severe toward wild type allele</td><td>WBC, fibroblasts</td><td><italic>AR</italic> in obligate heterozygotes</td></tr><tr><td>Borjeson–Forssman–Lehmann syndrome</td><td><p>Xq26.2-3</p><p>134,373,311</p></td><td><italic>PHF6</italic></td><td>301900</td><td><p>ID, obesity, hypogonadism, epilepsy,</p><p>facial dysmorphism</p></td><td><p>Mild ID</p><p>11 females with de novo variants have Coffin–Siris phenotype all skewed 100% toward mutant allele, female with 70% skewing had milder symptoms</p></td><td><p>Yes, severe toward wild type allele</p><p>If unskewed, then manifesting at least a little</p><p>If skewed severely toward mutant, then severe disease</p></td><td>WBC</td><td><italic>FMR1, AR PGK1</italic></td></tr><tr><td>Bruton agammaglobulinemia</td><td><p>Xq22.1</p><p>101,349,446</p></td><td><italic>BTK</italic></td><td>300300</td><td><p>B-cell deficiency; boys lack circulating B cells;</p><p>they are overcome by bacterial infections</p></td><td>No affected females</td><td>Yes, severe &gt;95%</td><td>B cells</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Cataract 40</bold></p><p><bold>Allelic with Nance–Horan syndrome</bold></p></td><td><p><bold>Xp22.1-22.2</bold></p><p><bold>17, 375,199</bold></p></td><td><p><bold><italic>NHS</italic></bold></p><p><bold>Lack of NHS leads to NH syndrome; milder variants give cataracts</bold></p></td><td>302200</td><td><p>Congenital cataracts with severe visual impairment &amp; microcornea</p><p>Associated with triplication of the locus</p></td><td>Normal vision but develop cataracts in their 40s</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Nance–Horan Syndrome</bold></td><td><p><bold>Xp22</bold></p><p><bold>17, 375,199</bold></p></td><td><bold><italic>NHS</italic></bold></td><td>302350</td><td>Congenital cataract leading to profound vision loss; dysmorphic features and malformed teeth Microcornea, microphthalmia, and mild or moderate ID</td><td>Slightly reduced vision</td><td>ND</td><td></td><td></td></tr><tr><td><p>Charcot–Marie–Tooth</p><p>CMTX1</p></td><td><p>Xq13.1</p><p>71,215,211</p></td><td><italic>GJB1</italic></td><td><p>302800</p><p>304040</p></td><td>Sensory &amp; peripheral neuropathies</td><td>Milder</td><td>No</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Charcot–Marie–Tooth</bold></p><p><bold>CMTX5</bold></p><p><bold>Allelic with DFNX1</bold></p><p><bold>&amp; PRPS1 related gout</bold></p></td><td><p><bold>Xq22.3</bold></p><p><bold>107,628,423</bold></p></td><td><bold><italic>PRPS1</italic></bold></td><td>311070</td><td>Optic atrophy, polyneuropathy, &amp; deafness</td><td>Milder</td><td>No skewing determines severity</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p>Charcot–Marie–Tooth</p><p>CMTX6</p></td><td><p>Xp22.11</p><p>24,465,226</p></td><td><italic>PDK3</italic></td><td>300905</td><td><p>1 three-generation family</p><p>Males more severe than females</p><p>Foot deformities, abnormal gait muscle weakness, sensory abnormalities</p></td><td>Subtle features such as hand tremor with age</td><td>ND</td><td></td><td></td></tr><tr><td>Christianson syndrome</td><td><p>Xq26.3</p><p>135,974,595</p></td><td><italic>SLC9A6</italic> (<italic>NHE6</italic>)</td><td>300231</td><td><p>Profound ID; mute; developmental regression; impaired ocular movements</p><p>Epilepsy; microcephaly; cerebellar and brain stem atrophy</p></td><td><p>Milder</p><p>Psychiatric disorders</p><p>Study of 20 female heterozygotes shows deficit in at least one neurocognitive domain (ID 20%, learning differences 31%, speech delays 30%, &amp; ADHD 20%); atypical parkinsonism, with age</p></td><td>ND</td><td></td><td></td></tr><tr><td><bold>CHILD syndrome</bold></td><td><p><bold>Xq28</bold></p><p><bold>152 830, 966</bold></p></td><td><p><bold><italic>NSDHL</italic></bold></p><p><bold>loss of function</bold></p><p><bold>missense &amp; nonsense</bold></p></td><td>308050</td><td>Fetal lethal</td><td>Hemidysplasia with Unilateral ichthyosis</td><td>Yes, (in mice)</td><td>Brain, skin, liver of <italic>Bare Patches</italic> mice</td><td><italic>NSDHL</italic> activity</td></tr><tr><td><p><bold>CK syndrome</bold></p><p><bold>Analogous to bare patches in mice</bold></p><p><bold>Allelic with CHILD syndrome</bold></p></td><td><p><bold>Xq28</bold></p><p><bold>152 830, 966</bold></p></td><td><p><bold><italic>NSDHL</italic></bold></p><p><bold>300275</bold></p><p><bold>hypomorphic variant</bold></p></td><td>300831</td><td><p>ID plus neonatal seizures</p><p>Only males affected;</p><p>Defect in cholesterol synthesis</p></td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td>Chondrodysplasia punctata 1</td><td><p>Xp22.23</p><p>2,934,631</p></td><td><p><italic>ARSE</italic></p><p>sometime small chromosomal deletions</p></td><td>302950</td><td><p>ID, bone defects;</p><p>short stature;</p><p>epiphyseal stippling</p></td><td>Milder symptoms</td><td><p>No</p><p>Mild cases not affected</p></td><td>WBC &amp; fetal tissues</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Chondrodysplasia punctata 2</bold></p><p><bold>(Conradi–Hunermann syndrome) CDPX2</bold></p><p><bold>Allelic with Mend syndrome</bold></p></td><td><p><bold>Xp11.23</bold></p><p><bold>48,521,807</bold></p></td><td><p><bold><italic>EPB</italic></bold></p><p><bold>Emopamil binding protein</bold></p></td><td>302960</td><td><p>Fetal lethal;</p><p>Facial skin and skeletal dysplasia</p><p>Only mosaic males survive</p></td><td><p>Bilateral ichthyosis</p><p>Short stature</p><p>Epiphyseal stippling</p><p>Hair and skin defects</p><p>Occasionally severe due to skewed XI</p></td><td>No</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Conradi–Hunermann–Happle syndrome CDPX2</bold></td><td><p><bold>Xp11.23</bold></p><p><bold>48,521,807</bold></p></td><td><bold><italic>EBP</italic></bold></td><td>302960</td><td><p>Mosaic grandfather (50%)</p><p>Short stature</p></td><td><p>Mother: short stature;</p><p>Mosaic skin defect</p><p>Fetus: severe bone abnormalities; no skin rash</p></td><td><p>Random XI in blood of both fetus &amp; mother (not shown)</p><p>Perhaps skewed in affected tissues</p></td><td>WBC</td><td><italic>AR</italic> splicing pathogenic variant in EBP causing extreme familial variability</td></tr><tr><td><bold>MEND syndrome</bold></td><td><p><bold>Xp11.23</bold></p><p><bold>48,521,807</bold></p><p><bold>missense</bold></p></td><td><p><bold><italic>EBP</italic></bold></p><p><bold>Hypomorphic variant</bold></p></td><td>300960</td><td>Nonmosaic; ID; short, scoliosis; abnormal digits; cataracts and dermatitis</td><td>Heterozygotes are usually unaffected</td><td>ND</td><td></td><td></td></tr><tr><td>Congenital disorder of glycosylation CDG2M</td><td><p>Xp11.23</p><p>48,903,182</p></td><td><p><italic>SLC35A2</italic></p><p>UDP galactose transporter</p><p>Loss of function</p></td><td>300896</td><td>All affected males are mosaics</td><td>Females are affected with infantile epileptic encephalopathy</td><td>Affected females with truncating variants are highly skewed toward wild type; one female with de novo splice site variant had random XI</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Chronic granulomatous disease</bold></td><td><p><bold>Xp21.1-11.4</bold></p><p><bold>37,780, 016</bold></p></td><td><p><bold><italic>CYBB</italic></bold></p><p><bold>Cytochrome B Beta subunit</bold></p></td><td>306400</td><td>Severe bacterial infections</td><td><p>Discoid lupus</p><p>Rare, severely affected female due to skewing</p></td><td>No</td><td>WBC, buccal</td><td><italic>AR</italic></td></tr><tr><td><bold>CGD (large study of 93 females only)</bold></td><td><p><bold>Xp21.1-11.4</bold></p><p><bold>37,780, 016</bold></p></td><td><bold><italic>CYBB</italic></bold></td><td>306400</td><td>Not applicable</td><td><p>Milder symptoms associated with higher dehydrorhodamine oxidation (DHR); low DHR associated with manifestations</p><p>No progressive skewing over time</p></td><td><p>Severe carriers had low DHR</p><p>Sisters &amp; twins highly correlated, but not with mothers</p></td><td>WBC</td><td>%DHR+</td></tr><tr><td><bold>Immunodeficiency 34</bold></td><td><p><bold>Xp21.1-11.4</bold></p><p><bold>37,780, 016</bold></p></td><td><p><bold><italic>CYBB</italic></bold></p><p><bold>missense &amp; nonsense variant</bold></p></td><td>300645</td><td>Severe mycobacterial infections (some TB)</td><td>Rare female</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>Coffin–Lowry</bold></p><p><bold>Allelic to XLMR 19</bold></p></td><td><p><bold>Xp22.12</bold></p><p><bold>20,149,910</bold></p></td><td><p><bold><italic>RPS6KA3</italic></bold></p><p><bold>(RSK2)</bold></p><p><bold>Small deletions &amp; small duplication</bold></p><p><bold>Missense variants</bold></p></td><td>303600</td><td>ID; short stature; abnormal facies, gait, &amp; fingers; microcephaly</td><td>Milder ID than male</td><td>Yes, all seem to have significant skewing; direction not clear save for 2 mothers with predominant wild type cells</td><td>WBC</td><td><italic>AR RSK2</italic></td></tr><tr><td><bold>X-linked mental retardation 19</bold></td><td><p><bold>Xp22.12</bold></p><p><bold>20,149,910</bold></p></td><td><p><bold><italic>RPS6KA3</italic></bold></p><p><bold>(RSK2)</bold></p><p><bold>Hypomorphic</bold></p></td><td>300854</td><td>Moderate ID with no other anomalies</td><td>Milder nonsyndromic ID</td><td>ND</td><td></td><td></td></tr><tr><td>Coagulation factor 8</td><td><p>Xq28</p><p>154,835,787</p></td><td>F8</td><td>306700</td><td>Severe &lt;1%, moderate 2–6% or mild 6–30% residual activity</td><td>Most heterozygotes have 50% so are clinically normal; affected if homozygous mutants or if XI skewed</td><td><p>No, but skewing causes manifestations.</p><p>Familial skewing in manifesting heterozygotes</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Coagulation factor 9</td><td><p>Xq27.1</p><p>139,530,719</p></td><td>F9</td><td>300746</td><td>Affected are mainly males</td><td>Affected females usually have skewed X-inactivation or are homozygous</td><td>No, but severe skewing responsible for manifesting heterozygotes</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Cornelia de Lange syndrome</bold></p><p><bold>5% cases attributed to</bold>
<bold><italic>SMC1A</italic></bold></p><p><bold>(Cornelia de Lange, 2)</bold></p></td><td><p><bold>Xp11.22</bold></p><p><bold>53,374,148</bold></p></td><td><p><bold><italic>SMC1A</italic></bold></p><p><bold>Missense</bold></p></td><td>300590</td><td><p>More severe and fetal lethal</p><p>ID, facial dysmorphisms, seizures, limb abnormalities</p></td><td><p>Most of the affected are females</p><p>ID, poor growth, microcephaly, dysgenesis of corpus callosum</p></td><td><p>Escape gene</p><p>ND</p></td><td></td><td></td></tr><tr><td><bold>Cornelia de Lange, 2</bold></td><td><p><bold>Xp11.22</bold></p><p><bold>53,374,148</bold></p></td><td><p><bold><italic>SMC1A</italic></bold></p><p><bold>Truncating variants</bold></p></td><td>300040</td><td>Fetal lethal</td><td>Infantile epilepsy</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>Cornelia</bold>
<bold>de Lange</bold></p><p>
<bold>5</bold></p><p><bold>Allelic with XLMR Wilson–Turner</bold></p></td><td><p><bold>Xq13.2</bold></p><p><bold>72,329,515</bold></p></td><td><bold><italic>HDAC8</italic></bold></td><td>300882</td><td><p>Facial dysmorphism;</p><p>ID; multiple congenital abnormalities</p></td><td>Milder</td><td>Extreme, with mutant allele inactive</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>XLMR Wilson–Turner</bold></p><p><bold>Allelic with Cornelia de Lange 5</bold></p></td><td><p><bold>Xq13.2</bold></p><p><bold>72,329,515</bold></p></td><td><p><bold><italic>HDAC8</italic></bold></p><p><bold>Point variants</bold></p></td><td>300269</td><td><p>ID, microcephaly</p><p>Craniofacial deformities</p></td><td>Milder</td><td>Yes, extreme</td><td>WBC</td><td></td></tr><tr><td>Craniofrontonasal syndrome</td><td><p>Xq13.1</p><p>68,828,996</p></td><td><p><italic>EFNB1</italic></p><p>Heterozygous loss of function</p></td><td>304110</td><td>Hypertelorism</td><td>Craniosynostosis; craniofacial asymmetry; hypertelorism; frontonasal dysplasia; skeletal abnormalities</td><td>No, variant produces cellular interference</td><td><p>Blood,</p><p>cranioperiosteum</p></td><td><italic>AR</italic> immunochemistry</td></tr><tr><td>Creatine transporter defect</td><td><p>Xq28</p><p>153,687,925</p></td><td><italic>SLC6A8</italic></td><td>300352</td><td>ID, speech delay, seizures</td><td>Milder</td><td>No</td><td>Skin fibroblasts, blood, hair roots</td><td><italic>AR</italic></td></tr><tr><td>Danon disease</td><td><p>Xq24</p><p>120,426,147</p></td><td><italic>LAMP2</italic></td><td>300257</td><td><p>ID, cardiomyopathy,</p><p>skeletal muscle weakness</p></td><td>Later onset</td><td><p>Discordant identical twins; complete skew for affected</p><p>Skew responsible for heterozygous phenotype</p></td><td>IPS T cells</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Deafness X-linked 1</bold></p><p><bold>Allelic with Charcot–Marie–Tooth 5</bold></p></td><td><p><bold>Xq22.3</bold></p><p><bold>107,628,423</bold></p></td><td><bold><italic>PRPS1</italic></bold></td><td>304500</td><td>Phenotypic spectrum with Charcot–Marie–Tooth Males more severe than females</td><td>Females have mild high pitch hearing loss</td><td>ND</td><td></td><td></td></tr><tr><td>Deafness, X-linked 4</td><td><p>Xp22.12</p><p>21,705,971</p></td><td><italic>SMPX</italic></td><td>300066</td><td><p>Nonsyndromic postlingual hearing loss</p><p>Earlier onset in males 2–10 years (mean 3.3 years)</p></td><td>Onset 3–48 years (mean 28.8)</td><td>XI skewing influences phenotype</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Dent disease1</bold></td><td><p><bold>Xp11.23</bold></p><p><bold>49,922,595</bold></p></td><td><bold><italic>CLCN5</italic></bold></td><td>300009</td><td><p>Nephrolithiasis</p><p>Proteinuria</p><p>Hypophosphotemic rickets</p></td><td><p>Less severe;</p><p>rare hypercalciuria;</p><p>almost never chronic renal disease</p></td><td>First cases show 1/1 and 2/4 cases of extreme skewing toward mutant in affected females</td><td>WBC &amp; urine sediment</td><td><italic>AR</italic> and deep sequencing</td></tr><tr><td><bold>Dent disease 2</bold></td><td><p><bold>Xq26.1</bold></p><p><bold>129,540,258</bold></p></td><td><p><bold><italic>OCRL1</italic></bold></p><p><bold>Mild variant of Lowe syndrome</bold></p></td><td>300535</td><td>Proteinuria; Hypercalcemia; Nephrocalcinosis. No renal tubular acidosis,</td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Dent disease 2 Digenic</bold></td><td><p><bold>Xp11.23</bold>,</p><p><bold>49,922,595</bold></p><p><bold>Xq26.1</bold></p><p><bold>129,540,258</bold></p></td><td><p><bold><italic>CLCN5</italic></bold><bold>, OCRL1</bold></p><p><bold>(digenic)</bold></p></td><td><p>300009</p><p>300535</p></td><td><p>Abnormal facies, ocular abnormalities, rickets,</p><p>delayed growth</p></td><td>Heterozygotes not affected</td><td>Yes, severe</td><td>WBC</td><td>mRNA</td></tr><tr><td>Diabetes insipidus (nephrogenic)</td><td><p>Xq28</p><p>159,902,624</p></td><td><italic>AVPR2</italic></td><td>304800</td><td><p>90% are X-linked (10% are autosomal); inability to concentrate urine;</p><p>unresponsive to antidiuretic hormone</p></td><td>Heterozygotes not affected</td><td><p>Asymptomatic heterozygotes have random XI</p><p>(4 heterozygotes normal with 50–60% XI) Skewing toward mutant leads to disease</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Dyskeratosis congenita</td><td><p>Xq28</p><p>154,762,741</p></td><td><italic>DKC1</italic></td><td>305000</td><td><p>Defective telomeres; premature aging;</p><p>bone marrow failure</p></td><td>None or milder</td><td>Yes, extreme</td><td>WBC, buccal multiple tissues</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Dystonia parkinsonism (XDP)</bold></p><p><bold>Filipino type</bold></p></td><td><p><bold>Xq13.1</bold></p><p><bold>71,366,219</bold></p></td><td><p><bold><italic>TAF1</italic></bold></p><p><bold>Retrotransposon insert</bold></p></td><td>314250</td><td>Adult onset dystonia and symptoms of Parkinson disease</td><td><p>Most heterozygotes not affected; a few affected have mild dystonia, later onset</p><p>manifestors said to have XI skewed</p><p> toward mutant, but no studies documented</p></td><td>ND</td><td></td><td></td></tr><tr><td><bold>XLID 33</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,366,219</bold></p></td><td><p><bold><italic>TAF1</italic></bold></p><p><bold>Missense variants</bold></p></td><td>300966</td><td><p>12 boys (9 families); global delay; syndromic ID hypotonia; facial dysmorphism; microcephaly</p><p>sacral caudal remnant</p></td><td>Heterozygotes not affected</td><td>Yes, 100% skewing toward normal allele</td><td>WBC</td><td><italic>AR</italic> &amp;<italic> RP2</italic> (only WT allele in RNA confirmed by PCR)</td></tr><tr><td><bold>Ectodermal dysplasia and immune deficiency</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,542,211</bold></p></td><td><p><bold><italic>IKBKG</italic></bold></p><p><bold>Hypomorphic variants with NF Kappa B activation</bold></p></td><td>300291</td><td><p>Fetal lethal or Dysglobulinemia. Recurrent infections, Osteopetrosis</p><p>Abnormal teeth</p></td><td>Heterozygotes not affected</td><td>Yes, severe, with gradual elimination of mutant T cells</td><td>T cells</td><td><italic>AR</italic></td></tr><tr><td>Ectodermal dysplasia</td><td><p>Xq13.1</p><p>61,616,085</p></td><td><p><italic>EDA</italic></p><p>Akin to tabby mouse</p><p>missense, nonsense deletion, &amp; splice junction variants</p></td><td>305100</td><td><p>Defective skin, hair, nails &amp; teeth</p><p>Variant interferes with rounding of cells by the cell membrane</p></td><td><p>Variable severity</p><p>Skewing correlated with disease severity</p></td><td>No</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Epileptic encephalopathy early infantile, 1</td><td><p>Xp21.3</p><p>25,003,693</p></td><td><italic>ARX</italic></td><td>308350</td><td>Spasms without brain malformations</td><td>Milder than males</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Epileptic encephalopathy early infantile, 2</bold></td><td><p><bold>Xp22.13</bold></p><p><bold>18,425,604</bold></p></td><td><p><bold>CDKL5</bold></p><p><bold>deletions</bold></p></td><td>300672</td><td>Infantile seizures, global delay subtle dysmorphic features; most die early</td><td><p>Milder than males</p><p>However, most heterozygotes affected…Males may die in utero? (32 deletions in females vs. 3 in males [Decipher])</p></td><td>No skewing</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Epileptic encephalopathy early infantile, 2</bold></td><td><p><bold>Xp22.13</bold></p><p><bold>18,425,604</bold></p></td><td><p><bold><italic>CDKL5</italic></bold></p><p><bold>missense</bold></p></td><td>300672</td><td>Some overlap with Rett; profound retardation and EEG abnormalities</td><td>Females less severe More apt to have hand stereotypies than males</td><td></td><td></td><td></td></tr><tr><td>Epileptic encephalopathy, early infantile, 8</td><td><p>Xq11.1</p><p>63,634,966</p></td><td><p>Collybistin</p><p><italic>ARHGEF9</italic></p></td><td>300429</td><td></td><td>Heterozygotes not affected unless skewed X-inactivation Manifesting females all have chromosome Translocation or deletion; 2 females with autism and intragenic deletions and no skewing</td><td><p>No, but manifesting requires complete skewing (mutant gene active)</p><p>Speculation: skewing in brain but not in blood</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Epileptic encephalopathy, early infantile, 9</td><td><p>Xq22</p><p>100,291,643</p></td><td><italic>PCDH19</italic></td><td>300088</td><td><p>Not affected</p><p>Mosaic males are affected</p></td><td><p>ID, Infantile seizures</p><p>Autism</p></td><td><p>ND</p><p>However, cellular interference thought to play a role</p></td><td></td><td></td></tr><tr><td>Epileptic encephalopathy, early infantile, 22</td><td><p>Xq11.23</p><p>48,903,182</p></td><td><italic>SLC35A2</italic></td><td>300896</td><td>See <italic>CDG2M</italic></td><td></td><td></td><td></td><td></td></tr><tr><td>Fabry disease</td><td><p>Xq22.1</p><p>101,397,790</p></td><td><italic>GLA</italic></td><td>301500</td><td>Progressive heart &amp; kidney disease</td><td><p>Attenuated</p><p>Females express because not a high uptake enzyme</p></td><td>No</td><td>Skin fibroblast clones</td><td><italic>GLA</italic></td></tr><tr><td>Fanconi anemia</td><td><p>Xp22.31</p><p>14,690,862</p></td><td><italic>FANCB</italic></td><td>300514</td><td>Bone marrow failure, predisposed to cancer</td><td>No affected females</td><td>Yes, extreme</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Focal dermal hypoplasia</bold></td><td><p><bold>Xp11.23</bold></p><p><bold>48,508,991</bold></p></td><td><p><bold><italic>PORCN</italic></bold></p><p><bold>Loss of function</bold></p></td><td>305600</td><td><p>Fetal lethal</p><p>Mosaic males survive, and have abnormalities, like females (10% of affected)</p></td><td><p>ID; skin atrophy &amp; pigmentation; multiple papillomas; abnormal digits,</p><p>striated bones; lobster claw</p></td><td><p>Microdeletions associated with severe skewing</p><p>Point variants not skewed</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Focal dermal hypoplasia</bold></td><td><p><bold>Xp11,23</bold></p><p><bold>48,508,991</bold></p></td><td><bold><italic>PORCN</italic></bold>
<bold>(missense)</bold></td><td>305600</td><td><p>2 nonmosaic survivors;</p><p>Missense variant inherited from mother</p></td><td>Random XI, but asymptomatic</td><td>No</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Fragile X syndrome</td><td><p>Xq27.3</p><p>147,911,918</p></td><td><italic>FMR1</italic></td><td>300624</td><td>XLID; congenital anomalies</td><td>Variable, milder</td><td>Yes, slight (full mutation)</td><td>WBC, skin fibroblasts</td><td><italic>FMR1</italic> methylation</td></tr><tr><td><bold>Glycogen storage disease 1Xa1 GSD9A1</bold></td><td><p><bold>Xp22.13</bold></p><p><bold>18,892,297</bold></p></td><td><p><bold><italic>PHKA2</italic></bold></p><p><bold>Complete loss of function</bold></p></td><td>306000</td><td><p>No PHK activity in liver &amp; RBCs</p><p>Yet mildest form of glycogen storage disease</p></td><td>Not usually affected</td><td>No</td><td>Skin fibroblasts</td><td><italic>PHK</italic> activity</td></tr><tr><td><bold>Glycogen storage disease 1Xa2 GSD9A1</bold></td><td><p><bold>Xp22.13</bold></p><p><bold>18,892,297</bold></p></td><td><p><bold><italic>PHKA2</italic></bold></p><p><bold>Missense enabling partial function</bold></p></td><td>306000</td><td><p>No PHK activity in liver;</p><p>even milder than above</p></td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td>Hemolytic anemia</td><td><p>Xq28</p><p>154,531,389</p></td><td><italic>G6PD</italic></td><td>305900</td><td>Chronic anemia</td><td>High dosages of primaquine; Rx for malaria cause hemolysis, if enough cells are mutant</td><td>Yes, slight with age</td><td>RBC, WBC</td><td><italic>G6PD</italic></td></tr><tr><td>Hunter syndrome (MPS2)</td><td><p>Xq28</p><p>149,505,353</p></td><td><italic>IDS</italic></td><td>309900</td><td>Mucopolysaccharidosis</td><td>Rarely affected unless skewed</td><td>No</td><td>Skin fibroblast clones</td><td><italic>IDS</italic></td></tr><tr><td><bold>Hydrocephalus, X-linked (due to aquaductal stenosis) allelic with MASA</bold></td><td><p><bold>Xq28</bold></p><p><bold>153,861,513</bold></p></td><td><bold><italic>L1CAM</italic></bold></td><td>307000</td><td><p>Only males affected</p><p>ID, spastic paraplegia</p><p>Some have clasped thumb</p></td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>MASA syndrome</bold></p><p><bold>SPG1</bold></p></td><td><p><bold>Xq28</bold></p><p><bold>153,861,513</bold></p></td><td><p><bold><italic>L1CAM</italic></bold></p><p><bold>same variants</bold></p></td><td>303350</td><td><p>Spastic paraplegia, aphasia,</p><p>ID, abducted thumb, but no congenital hydrocephalus</p><p>Family can segregate MASA or hydrocephalus phenotypes</p></td><td>Mild ID, abducted thumbs</td><td>ND</td><td></td><td></td></tr><tr><td>Hypophosphatemic rickets</td><td><p>Xp22.1</p><p>22,032,324</p></td><td><italic>PHEX</italic></td><td>307800</td><td><p>Short stature; rickets;</p><p>bone deformities</p></td><td>Heterozygotes variably affected</td><td>ND</td><td></td><td></td></tr><tr><td>Ichthyosis</td><td><p>Xp22.31</p><p>7,147,289</p></td><td><italic>STS</italic></td><td>308100</td><td><p>Extensive body ichthyosis,</p><p>corneal opacities</p></td><td><p>Late corneal opacities</p><p>Expressed from XI</p></td><td>No (point variant)</td><td><p>Skin fibroblast clones</p><p>Escape gene; 1/3 activity of XA</p></td><td><italic>STS</italic> &amp; <italic>G6PD</italic></td></tr><tr><td><bold>Immunodeficiency 33</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,542,239</bold></p></td><td><bold><italic>NEMO</italic></bold>
<bold>variants disrupt leucine zipper</bold></td><td>300636</td><td>Infections limited to mycobacteria</td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>Incontinentia pigmenti IP2</bold></p><p><bold>Allelic with immunodeficiency 33</bold></p></td><td><p><bold>Xq28</bold></p><p><bold>154,542,239</bold></p></td><td><p><bold><italic>NEMO</italic></bold></p><p><bold><italic>IKBKG</italic></bold>
<bold>variants</bold></p><p><bold>Usually deletions eliminating NF Kappa B activation</bold></p></td><td>308300</td><td>Fetal lethal usually; milder (hypomorphic) <italic>IKBKG</italic> variants lead to osteopetrosis in males only</td><td><p>Cell death causes rash along Blaschko lines</p><p>Abnormal hair and teeth</p><p>Females with hypomorphic IKBKG variants do not have osteopetrosis</p></td><td>Yes, severe skewing toward wild type, even with milder variants that permit male survival</td><td>Blood, WBC, Skin fibroblast clones</td><td><italic>HPRT</italic> &amp; G6PD</td></tr><tr><td>Immunodysregulation, polyendocrinopathy, and enteropathy (IPEX)</td><td><p>Xp11.23</p><p>49,250,435</p></td><td><p><italic>FOXP3</italic></p><p>(<italic>Scurfin</italic>)</p><p><italic>Scurfy</italic> in mice</p></td><td>304790</td><td><p>Immunological disorder; diabetes mellitus, dermatitis and enteropathy, onset in infancy; death by 2 years unless treated by immunosuppression and blood cell transplantation;</p><p>absence of islets of Langerhans; presents as severe diarrhea</p></td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Kabuki syndrome 2</bold></td><td><p><bold>Xp11.3</bold></p><p><bold>44,873,174</bold></p></td><td><p><bold><italic>KDM6A</italic></bold>
<bold>or</bold>
<bold><italic>UTX</italic></bold></p><p><bold>(mediates removal of trimethylation of histone H3, at HOX promoters</bold>,</p><p><bold>demethylates H3K27; methylates H3K4)</bold></p></td><td>300867</td><td><p>ID</p><p>Dwarfism, Kabuki facies, skeletal abnormalities; UTY protects</p></td><td><p>Like males</p><p>Some say females less severe than males—perhaps due to skewing disfavoring deletions</p><p>Escape may not protect females more than males as males also have an allele (UTY) on their Y chromosome</p></td><td><p>If deletion, then skewed; if variant, not skewed</p><p>Escapes XI</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Keipert syndrome</bold></p><p><bold>Allelic with Simpson–Golabi–Behmel syndrome</bold></p></td><td><p><bold>Xq26.2</bold></p><p><bold>133,300,102</bold></p></td><td><p><bold><italic>GPC4</italic></bold></p><p><bold>Missense variants</bold></p><p><bold>Duplications cause Simpson–Golabi–Behmel syndrome</bold></p></td><td>301026</td><td><p>Craniofacial dysmorphisms; foot and hand abnormalities;</p><p>mild intellectual disability</p></td><td>Carrier females are clinically unaffected, because all are &gt;90% skewed toward wild type</td><td>Yes, severe in blood</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Kelly–Seegmiller syndrome</bold></p><p><bold>(gout, X-linked)</bold></p><p><bold>Allelic with Lesch–Nyhan syndrome</bold></p></td><td><p><bold>Xq26.2</bold></p><p><bold>134,460,164</bold></p></td><td><p><bold><italic>HPRT</italic></bold></p><p><bold>308000</bold></p><p><bold>(partial, &lt;95% deficiency)</bold></p></td><td>300323</td><td>Uric acid stones leading to gouty arthritis</td><td>Heterozygotes not affected</td><td>No</td><td>WBC</td><td></td></tr><tr><td><p><bold>Lesch–Nyhan syndrome</bold></p><p><bold>Allelic with X-linked gout</bold></p></td><td><p><bold>Xq26.2</bold></p><p><bold>134,460,164</bold></p></td><td><p><bold><italic>HPRT</italic></bold></p><p><bold>308000</bold></p><p><bold>(&gt;98% deficiency)</bold></p></td><td>300322</td><td><p>ID,</p><p>spastic cerebral palsy,</p><p>uric acid stones, self-destructive biting</p></td><td>Heterozygotes not affected</td><td><p>Yes, severe (blood)</p><p>No in skin because of gap junctions</p></td><td><p>RBC, WBC, skin fibroblast</p><p> clones</p></td><td><italic>HPRT, G6PD</italic></td></tr><tr><td>Lissencephaly &amp; agenesis of the corpus callosum</td><td><p>Xq22.3-q23</p><p>111,293,778</p></td><td><italic>DCX</italic></td><td>300067</td><td>ID, brain malformation due to neural migration defect seizures</td><td>Mild epilepsy (subcortical band heterotopia) or normal</td><td>No</td><td>Blood</td><td><italic>AR</italic></td></tr><tr><td>Lowe syndrome</td><td><p>Xq26.1</p><p>129,540,258</p></td><td><italic>OCRL1</italic></td><td>309000</td><td>ID; cataracts; rickets; aminoaciduria</td><td>Heterozygotes not affected</td><td>(100%) in one manifesting heterozygote unrelated to variant</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p>Severe systemic lupus</p><p>erythematosis</p></td><td><p>Xp22.2</p><p>12,867,071</p></td><td><italic>TLR7</italic></td><td>300365</td><td>Rarely affected, except if XXY</td><td>Females 9 times frequency of males</td><td><p>ND</p><p>Escape from inactivation in all females;</p><p>B lymphocytes, monocytes and plasmacytoid dendritic cells</p></td><td></td><td></td></tr><tr><td>Lymphoproliferative syndrome 2 XLP2</td><td><p>Xq25</p><p>123,859,811</p></td><td><p><italic>XIAP</italic> inhibitor of apoptosis</p><p><italic>BIRC4</italic></p></td><td>300079</td><td><p>Pancytopenia, splenomegaly,</p><p>pancolitis</p></td><td><p>Usually heterozygotes not affected</p><p>Occasionally female affected due to skewing toward mutant cells</p></td><td>Yes, in hematopoietic cells</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p>Lymphoproliferative syndrome</p><p><italic>XLP1</italic> (Duncan disease)</p></td><td><p>Xq25</p><p>124,346,281</p></td><td><italic>SH2D1A</italic></td><td><p>308240</p><p>300490</p></td><td><p>Severe immunodeficiency especially after EB virus infection; severe or fatal mononucleosis; acquired hypogammaglobulinemia;</p><p>hemophagocytic lymphohistiocytosis (HLH), and/or malignant lymphoma</p></td><td>No reported affected females (probably because both skewing plus exposure to EB virus needed)</td><td>Carrier female had complete skewing toward wild type in NK cells but not in T or B cells</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Mediator complex subunit 12</bold></p><p><bold>MED12</bold></p><p><bold>Allelic with Lujan–Fryns syndrome (309520); Ohdo syndrome (300895); Opitz–Kaveggia syndrome (305450)</bold></p></td><td><p><bold>Xq13.1</bold></p><p><bold>71,118,595</bold></p></td><td><p><bold><italic>MED12</italic></bold>
<bold>or</bold>
<bold><italic>HOPA</italic></bold></p><p><bold>Transcriptional activator &amp; repressor</bold></p><p><bold>Different variants cause different syndromes</bold></p><p><bold>Missense variant</bold></p></td><td>300188</td><td><p>ID plus</p><p>tall stature</p><p>(all hemizygous missense variants; different missense variants in same gene)</p><p>ID plus macrocephaly; hypotonia; absence of corpus callosum</p></td><td>Infrequent &amp; milder</td><td>See below</td><td></td><td></td></tr><tr><td><bold>Lujan–Fryns Syndrome</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,118,595</bold></p></td><td><bold><italic>MED12</italic></bold>
<bold>or</bold>
<bold><italic>HOPA</italic></bold>
<bold>point variant in exon 22</bold></td><td>309520</td><td>Marfanoid habitus; long, narrow face; moderate ID;</td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Ohdo syndrome</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,118,595</bold></p></td><td><p><bold><italic>MED12</italic></bold>
<bold>or</bold>
<bold><italic>HOPA</italic></bold></p><p><bold>Missense variants</bold></p></td><td>300895</td><td><p>Blepharophimosis; ptosis;</p><p>cryptorchidism; ID</p></td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Opitz–Kaveggia syndrome</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,118,595</bold></p></td><td><p><bold><italic>MED12</italic></bold>
<bold>or</bold>
<bold><italic>HOPA</italic></bold></p><p><bold>Missense variants</bold></p><p><bold>C-T transition in exon 21</bold></p></td><td>305450</td><td>ID; macrocephaly; hypotonia &amp; imperforate anus; partial or complete absence of the corpus callosum; often cryptorchidism</td><td>Much milder; hypertelorism; normal IQ</td><td>Variable; Four of 18 heterozygotes showed significant skewing but in different directions</td><td>WBC</td><td><italic>AR</italic> &amp; <italic>FMR1</italic></td></tr><tr><td><p><bold>Melnick–Needles syndrome</bold></p><p><bold>See OPD1</bold></p></td><td><p><bold>Xq28</bold></p><p><bold>154,348,530</bold></p></td><td><bold><italic>FLNA</italic></bold></td><td>309350</td><td><p>1 of 4 otopalatodigital syndromes caused by variants in <italic>FLNA</italic>; most are severe; prenatal mortality or perinatal death</p><p>Severe congenital abnormalities</p></td><td><p>Most affected have much milder phenotype;</p><p>mild deformity of bones</p></td><td><p>Yes, likely</p><p>skewed toward the normal allele because of cell selection</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Menkes syndrome</bold></p><p><bold>Allelic with occipital horn syndrome &amp; spinal muscular atrophy</bold></p></td><td><p><bold>Xq21.1</bold></p><p><bold>77,910,655</bold></p></td><td><p><bold><italic>ATP7A</italic></bold></p><p><bold>Truncation</bold></p></td><td>309400</td><td>Copper deficiency</td><td>Heterozygotes not affected</td><td><p>Yes, severe</p><p>Caveat: 15-kb deletion</p></td><td><p>WBC, lymphoblasts,</p><p>skin fibroblasts</p></td><td><italic>AR</italic></td></tr><tr><td><p>Methylmalonic acidemia</p><p>Also referred to as XLMR 45</p></td><td><p>Xq28</p><p>153,947,555</p></td><td><p><italic>HCFC1</italic></p><p>Host cell factor C1</p><p>300019</p><p>Missense</p></td><td>309541</td><td>Nonsyndromic ID</td><td><p>Normal IQ</p><p>Highly skewed XI</p></td><td>Yes, severe</td><td><p>WBC</p><p>Data not shown</p></td><td></td></tr><tr><td><p><bold>Microophthalmia syndrome 2 (MCOPS2)</bold></p><p><bold>Allelic with OFCD</bold></p></td><td><p><bold>Xp11,4</bold></p><p><bold>40,051,245</bold></p></td><td><p><bold><italic>BCOR</italic></bold>
<bold>300485</bold>
<bold>(See OFCD)</bold></p><p><bold>Premature stop codons</bold></p></td><td>300166</td><td>Male lethal</td><td><p>Congenital cataract, microopthalmia</p><p>Cardiac abnormalities</p><p>Dental abnormalities</p></td><td>ND</td><td></td><td></td></tr><tr><td>Microphthalmia, syndromic 7 (MCOPS7)</td><td><p>Xp22</p><p>11,111,331</p></td><td><p><italic>HCCS</italic></p><p>microdeletions</p></td><td>300056</td><td><p>Male lethal</p><p>Due to OXPHOS defect</p></td><td><p>Wide spectrum ranging from asymptomatic to corneal opacity;</p><p>microphthalmia;</p><p>linear skin defects; microcephaly; cardiac defects</p></td><td>Severe; complete or moderate (&gt;80%) skewing Favoring normal allele (in blood cells)</td><td>WBC</td><td><italic>AR, MAOA, PGK FMR1</italic></td></tr><tr><td>Monoamine oxidase A deficiency (Brunner syndrome)</td><td><p>Xp11.3</p><p>43,654,906</p></td><td><italic>MAOA</italic></td><td>300615</td><td>Mild ID; aggressive impulsive behavior</td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><p>Muscular dystrophy,</p><p>Duchenne</p></td><td><p>Xp21</p><p>31,119,218</p></td><td><italic>DMD</italic></td><td>310200</td><td><p>Muscular dystrophy</p><p>Mild ID</p></td><td>Only when unrelated skew favors mutant cells</td><td>No</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p>Muscular dystrophy,</p><p>Emery–Dreifuss</p></td><td><p>Xq28</p><p>154,379,235</p></td><td><italic>EMD</italic></td><td>310300</td><td><p>Muscular dystrophy;</p><p>heart arrhythmias</p></td><td>No affected females</td><td>ND</td><td></td><td></td></tr><tr><td>Myotubular myopathy</td><td><p>XQ28</p><p>150,673,142</p></td><td><italic>MTM1</italic></td><td>300415</td><td>Respiratory failure during 1st year; severe hypotonia</td><td><p>Asymptomatic, or mild weakness</p><p>Some females skewed and symptomatic</p><p>One female skewed 70:30 in muscle, and 55:45 in blood</p></td><td><p>NO or ND</p><p>Histology (I think) looking for ragged fibers</p></td><td>55:45 method not presented</td><td></td></tr><tr><td><p><bold>Neurodegeneration with brain</bold></p><p><bold>iron accumulation (NBIA5)</bold></p></td><td><p><bold>Xp11.23</bold></p><p><bold>49,074,432</bold></p></td><td><p><bold><italic>WDR45</italic></bold>
<bold>(all de novo)</bold></p><p><bold>Most truncating or partial deletion</bold></p></td><td><bold>300894</bold></td><td><p>Fetal lethal,</p><p>Mosaics survive to be affected</p></td><td><p>Static encephalopathy of childhood with neurodegeneration in adulthood;</p><p>parkinsonism; dystonia; dementia</p></td><td>Only rare, severely skewed toward wild type females survive to manifest</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td></td><td><p><bold>Xp11.23</bold></p><p><bold>49,074,432</bold></p></td><td><p><bold><italic>WDR45</italic></bold></p><p><bold><italic>BPAN</italic></bold>
<bold>variant</bold></p></td><td><bold>300894</bold></td><td>Occasional missense variant or germline mosaicism, but most males die in utero</td><td>Infantile spasms; developmental delay; ID; absent to limited language; Parkinson disease and dystonia develop with age</td><td><p>Skewed X-inactivation 2:98 in 11-year-old female</p><p>Several older females with normal allele preferentially inactivated</p></td><td>WBC</td><td><italic>AR?</italic></td></tr><tr><td>Neurite extension &amp; migration Factor</td><td><p>Xq13.3</p><p>74,732,855</p></td><td><p><italic>NEXMIF</italic> formerly <italic>KIA2022</italic></p><p>See <italic>XLID98</italic></p></td><td>300524</td><td>XLID</td><td>Less severe</td><td><p>No</p><p>36–64%</p></td><td>WBC</td><td>Methylation?</td></tr><tr><td><p>Night blindness (congenital)</p><p>type 1A <italic>CSNB1A</italic></p></td><td><p>Xp11.4</p><p>41,447,459</p></td><td><italic>NYX</italic> (nyctalopia)</td><td>310500</td><td>Myopia and night blindness; rod function absent</td><td><p>14 daughters of 9 affected males were not affected</p><p>However, some heterozygotes are and may reflect skewing—or are homozygous for the variant</p></td><td>ND</td><td></td><td></td></tr><tr><td>Night blindness (congenital stationary incomplete) type 2A</td><td><p>Xp11.23</p><p>49,205,062</p></td><td><italic>CACNA1F</italic></td><td>300071</td><td><p>Nonprogressive retinal disorder with myopia and nystagmus</p><p>No deterioration</p></td><td>6 obligate carriers had no symptoms</td><td>ND</td><td></td><td></td></tr><tr><td>Nystagmus 1 (congenital)</td><td><p>Xq26,2</p><p>132,074,925</p></td><td><italic>FRMD7</italic></td><td>310700</td><td>Infantile, periodic, alternating</td><td><p>53% of carriers are affected</p><p>Some have skewed X-inactivation</p></td><td><p>Findings not interpretable</p><p>Perhaps wrong tissue analyzed</p></td><td><p>Actual data not shown</p><p>One normal skewed; other normals at 50–60%</p><p>Four affected skewed; two nonskewed</p></td><td><italic>AR</italic></td></tr><tr><td><p>Ogden syndrome</p><p>Some variants cause microphthalmia syndrome (309800)</p></td><td><p>Xq28</p><p>153,929,224</p></td><td><italic>NAA10</italic></td><td>300855</td><td>Delayed psychomotor development; dysmorphic facial features; scoliosis, and cardiac dysfunction with long QT syndrome</td><td><p>1 severe female (with loss of function variant; another mild ID</p><p>Wide spectrum depending on nature of variant; females with same variant as males are usually milder</p></td><td>4/4 nonaffected Heterozygotes have 90-100% skewing</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Oculofaciocardiodental syndrome</bold></p><p><bold>Microphthalmia syndrome 2</bold></p></td><td><p><bold>Xp11.4</bold></p><p><bold>40,051,245</bold></p></td><td><bold><italic>BCOR</italic></bold>
<bold>null</bold></td><td>300166</td><td>Death in utero</td><td><p>OFCD</p><p>Early onset cataracts</p><p>Radiculomegaly of canine teeth</p><p>Cardiac septal defects</p><p>Facial dysmorphism</p></td><td>Some skewing toward wild type</td><td></td><td></td></tr><tr><td><p><bold>X-linked BCOR-related syndrome</bold></p><p><bold>Lenz microphthalmia</bold></p></td><td><p><bold>Xp11.4</bold></p><p><bold>40,051,245</bold></p></td><td><p><bold><italic>BCOR</italic></bold>
<bold>variant</bold></p><p><bold>C to T transition</bold></p></td><td>300485</td><td><p>Microphthalmia syndrome</p><p>Severe microphthalmia</p><p>Some variants have no eye abnormalities, but MR</p></td><td>Heterozygotes not affected</td><td>100% skewing</td><td></td><td></td></tr><tr><td><p><bold>Orofaciodigital syndrome (OFD1)</bold></p><p><bold>Allelic with Simson–Galabia–Beheld syndrome 2 &amp; Joubert syndrome</bold></p></td><td><p><bold>Xp22.2</bold></p><p><bold>13,734,712</bold></p></td><td><bold><italic>OFD1</italic></bold>
<bold>(</bold><bold><italic>CXORF5</italic></bold><bold>)</bold></td><td><bold>311200</bold></td><td><p>Fetal lethal</p><p>A ciliopathy</p></td><td>Malformations of face &amp; digits; polycystic kidneys</td><td><p>No human gene escapes XI</p><p>In mice no escape and neonatal mouse females die of polycystic kidneys</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td></td><td></td><td><bold>4</bold>-<bold>bp deletion in</bold>
<bold><italic>OFD1</italic></bold>
<bold>causing frameshift</bold></td><td></td><td></td><td></td><td>Mother (not affected) has random XI but affected daughter is skewed toward mutant allele</td><td></td><td></td></tr><tr><td><p><bold>Joubert syndrome 10</bold></p><p><bold>Allelic with Simpson–Golabi–Behmel, and OFD1</bold></p></td><td><p><bold>XP22.2</bold></p><p><bold>13,734,712</bold></p></td><td><p><bold><italic>OFD1</italic></bold></p><p><bold>Small deletions</bold></p></td><td>300804</td><td><p>Ciliary dysfunction</p><p>Hypotonia</p><p>Cerebellar ataxia</p></td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>Simpson–Golabi–Behmel syndrome type 2</bold></p><p><bold>Allelic with OFD1</bold></p></td><td><p><bold>Xp22.1</bold></p><p><bold>13,734,712</bold></p></td><td><p><bold><italic>OFD1</italic></bold></p><p><bold>4</bold>-<bold>bp deletion</bold></p></td><td>300209</td><td>One family of 9 males; most die early but one had severe ID, facial dysmorphisms, obesity, &amp; repeated respiratory infections; respiratory cilia disorganized and uncoordinated</td><td>Heterozygotes not affected</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Oropalatodigital syndrome 1</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,348,530</bold></p></td><td><p><bold><italic>FLNA</italic></bold></p><p><bold>Mildest of spectrum</bold></p></td><td>311300</td><td>Cleft palate, conductive hearing loss; mild skeletal abnormalities &amp; renal failure</td><td>Some mild symptoms</td><td><p>No, but skewing</p><p> causes manifestation</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Oropalatodigital syndrome 2</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,348,530</bold></p></td><td><p><bold><italic>FLNA</italic></bold></p><p><bold>Gain of function variants</bold></p></td><td>304120</td><td>Disabling skeletal anomalies, variable brain, cardiac, intestinal anomalies</td><td>Milder symptoms, some facial dysmorphism</td><td></td><td></td><td></td></tr><tr><td><bold>Melnick–Needles syndrome</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,348,530</bold></p></td><td><p><bold><italic>FLNA</italic></bold></p><p><bold>Most severe</bold></p></td><td>309350</td><td>Fetal lethal</td><td>Skeletal dysplasia</td><td>Yes? Skewing in blood toward normal in 3 affected heterozygotes, but FLNA interacts with AR so assay may not be valid</td><td>WBC</td><td></td></tr><tr><td><bold>Frontometaphyseal dysplasia</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,348,530</bold></p></td><td><bold><italic>FLNA</italic></bold></td><td>305620</td><td>Frontal bone overgrowth, scoliosis, facial dysmorphism; increased bone density; occasional renal abnormality</td><td>Normal, or mild hyperosteosis</td><td>ND</td><td></td><td></td></tr><tr><td>Ornithine transcarbamylase deficiency</td><td><p>Xp11.4</p><p>38,352,527</p></td><td><italic>OTC</italic></td><td>311250</td><td><p>Urea cycle disorder;</p><p>males die in infancy of severe disease unless treated</p></td><td><p>85% are symptomatic with hyperammonemia</p><p>20–30% activity not enough</p></td><td>No, but skewing in liver, not WBCs, corresponds with severity</td><td>WBC &amp; Liver</td><td></td></tr><tr><td>PDC deficiency</td><td><p>Xp22.12</p><p>19,343,892</p></td><td><p><italic>PDHA1</italic></p><p>pyruvate dehydrogenase complex, E1-ɑ polypeptide 1</p></td><td>312170</td><td><p>a) Neonatal lactic acidosis; encephalopathy; brain malformations; early death</p><p>b) Infantile or childhood-onset Leigh syndrome</p><p>c) Milder relapsing disorder of ataxia dystonia and peripheral neuropathy</p></td><td><p>Dysmorphic features; microcephaly; moderate or severe psychomotor delay; spastic di/quadriplegia &amp; epilepsy (cortical atrophy, cyst &amp; corpus callosum agenesis);</p><p>all heterozygous; more severe variant than in males</p><p>Missense variants are milder</p></td><td>No, but skewing determines severity of phenotype</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Pelizaeus–Merzbacher</td><td><p>Xq22.2</p><p>103,776,505</p></td><td><p><italic>PLP1</italic> point variant</p><p>Often duplications of Xq22.2</p></td><td>312080</td><td><p>Myelin leukodystrophy</p><p>Spastic diplegia</p></td><td><p>No symptoms or milder;</p><p>Rare female affected due to skewing toward mutant cells</p><p>Some mild affected have no skewing because variant not severe enough to skew</p></td><td>During CNS development, oligodendrocytes with severe <italic>PLP1</italic> mutant alleles are negatively selected (apoptosis) in favor of wild type cells, with cell type specific skewed XI</td><td>WBC, lymphoblasts</td><td><italic>AR</italic></td></tr><tr><td>PIH1D3</td><td><p>Xq22.3</p><p>107,206,610</p></td><td><p><italic>PIH1D3</italic> formerly <italic>Cxorf41</italic></p><p>Expressed primarily in testes</p></td><td>300933</td><td><p>Primary ciliary dyskinesia;</p><p>nonsyndromic ODA; respiratory infections; chronic otitis; infertility with mutant sperm</p></td><td><p>Heterozygotes not affected</p><p>Normal fertility</p></td><td>ND</td><td></td><td></td></tr><tr><td><p><bold>Phosphoribosyl pyrophosphate</bold></p><p><bold>synthetase 1 spectrum</bold></p></td><td><p><bold>Xq22.3</bold></p><p><bold>107,628,423</bold></p></td><td><p><bold><italic>PRPS1</italic></bold></p><p><bold>Gain of function</bold></p></td><td>300661</td><td>Hyperuricemia; gout; deafness and neurological misfunction</td><td>His mother had gout, uric acid stones and hearing loss</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Charcot–Marie–Tooth</bold></td><td><p><bold>Xq22.3</bold></p><p><bold>107,628,423</bold></p></td><td><p><bold><italic>PRPS1</italic></bold></p><p><bold>Reduced expression</bold></p></td><td>311070</td><td><p>Peripheral neuropathy; deafness; visual impairment;</p><p>no increased uric acid</p></td><td>Not affected or milder</td><td>Variable skewing consistent with phenotype</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Arts syndrome</bold></td><td><p><bold>Xq22.3</bold></p><p><bold>107,628,423</bold></p></td><td><p><bold><italic>PRPS1</italic></bold></p><p><bold>Reduced expression</bold></p></td><td>301835</td><td>ID; hypotonia; ataxia; hearing impairment and optic atrophy</td><td>Milder but continuous spectrum depending on extent of skewing</td><td>Variable skewing consistent with phenotype</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>DFNX1</bold></td><td><p><bold>Xq22.3</bold></p><p><bold>107,628,423</bold></p></td><td><p><bold><italic>PRPS1</italic></bold></p><p><bold>Missense variant</bold></p><p><bold>40–70% reduced activity</bold></p></td><td>304500</td><td>Deafness</td><td><p>Spectrum of phenotypes</p><p>Usually milder</p></td><td>ND</td><td></td><td></td></tr><tr><td>Protoporphyria (X-linked erythropoietic)</td><td><p>Xp11.21</p><p>55,009,054</p></td><td><p><italic>ALAS2</italic></p><p>Increased activity</p><p>gain of function</p></td><td>300752</td><td>RBC porphyria</td><td><p>11 females vary in phenotype with skewing of XI correlated with degree of severity</p><p>Example of no X-linked dominant disease</p></td><td>No selection, but skewing influences phenotype</td><td>Blood DNA</td><td><italic>AR</italic> &amp; <italic>ZMYM3</italic></td></tr><tr><td>Raynaud–Claes syndrome</td><td><p>Xp22.2</p><p>10,156,944</p></td><td><p><italic>CLCN4</italic></p><p>Chloride/hydrogen ion exchanger</p><p>truncated and missense</p><p>frameshift</p></td><td>300114</td><td><p>Severe ID &amp; epilepsy</p><p>Impaired language</p></td><td>Milder</td><td><p>Not shown;</p><p>No obvious selection</p></td><td>WBC</td><td>?? Poor study</td></tr><tr><td>Renpenning syndrome</td><td><p>Xp11.23</p><p>48,897,861</p></td><td><p><italic>PQBP1</italic></p><p>Polyglut binding protein 1</p></td><td>300463</td><td>MR; short stature, microcephaly</td><td>Unaffected, but skewed XI</td><td>Highly skewed</td><td>WBC</td><td><italic>AR, FMR1</italic></td></tr><tr><td><bold>Retinitis pigmentosis 3</bold></td><td><p><bold>Xp11.4</bold></p><p><bold>38,269,162</bold></p><p><bold>Loss of function; hot spot in exon 15</bold></p></td><td><bold><italic>RPGR</italic></bold></td><td>300029</td><td>Inherited choroidal retinal degeneration; destroys rod photoreceptors; become blind</td><td>All heterozygotes have tapetal-like retinal reflex; some heterozygotes are affected—usually milder, but variable; rarely legally blind</td><td>ND</td><td></td><td></td></tr><tr><td><bold>X-linked cone–rod dystrophy</bold></td><td><p><bold>Xp11.4</bold></p><p><bold>38,269,162</bold></p><p><bold>variants in alternate exon 15</bold></p></td><td><bold><italic>RPGR</italic></bold></td><td>304020</td><td>Progressive loss of vision</td><td>Not affected, but detectable by visual testing</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Syndromic retinitis pigmentosa</bold></td><td><p><bold>Xp11.4</bold></p><p><bold>38,269,162</bold></p></td><td><bold><italic>RPGR</italic></bold></td><td>300455</td><td>RP3 with sinorespiratory infections, with or without deafness</td><td>Often affected, but milder</td><td>ND</td><td></td><td></td></tr><tr><td><bold>Rett syndrome</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,021,572</bold></p></td><td><p><bold><italic>MECP2</italic></bold></p><p><bold>point variant</bold></p></td><td><p>312750</p><p>300005</p></td><td><p>Fetal lethal;</p><p>mosaic males have Rett syndrome; some males without obvious mosaicism survive;</p><p>severity dependent on mosaicism &amp; variant</p></td><td>MR; arrested development; impaired speech; handwringing</td><td><p>No, unless large deletion;</p><p>Blood DNA does not always reflect brain DNA</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Lubs XLID</bold></p><p><bold>Allelic with Rett syndrome</bold></p></td><td><p><bold>Xq28</bold></p><p><bold>154,021,572</bold></p></td><td><bold><italic>MECP2</italic></bold>
<bold>duplication</bold></td><td>300260</td><td>Affected males have Rett phenotype; moderate to severe ID; seizures</td><td>Unaffected because of extreme skewing</td><td>Extreme skewing</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Sick sinus syndrome</bold></td><td><p><bold>Xq28</bold></p><p><bold>154,021,572</bold></p></td><td><p><bold><italic>MECP2</italic></bold>
<bold>deletion</bold></p><p><bold>(0.6 deletion effecting TDR)</bold></p></td><td>Not yet given</td><td>Autonomic NS affected in two brothers</td><td>Milder symptoms</td><td>Extreme skewing in unaffected mother</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>Simpson–Golabi–Behmel syndrome type 1</td><td><p>Xq26.2</p><p>133,535,744</p></td><td><p><italic>GPC3</italic></p><p>Duplication of <italic>GPC3</italic> &amp; <italic>GPC4</italic> produce some affected females, but skewing toward mutant needed</p></td><td>312870</td><td><p>Congenital malformations &amp; overgrowth</p><p>ID, macrocephaly, cleft palate</p></td><td><p>Rare; usually unaffected or much milder</p><p>Rarely affected;</p><p>Female with a small Xq26 microduplication is affected; she has random XI</p></td><td><p>No; skewing toward mutant produces symptoms</p><p>Normal females not skewed</p></td><td>?</td><td></td></tr><tr><td><p><bold>SCIDX1</bold></p><p><bold>Severe combined immunodeficiency</bold></p></td><td><p><bold>Xq13.1</bold></p><p><bold>71,107,403</bold></p></td><td><bold><italic>IL2RG</italic></bold></td><td>300400</td><td>B- &amp; T-cell immunodeficiency</td><td>Heterozygotes not affected</td><td>Yes, extreme</td><td>T &amp; B cells</td><td>Cell count</td></tr><tr><td><bold>CIDX1</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,107,403</bold></p></td><td><bold><italic>IL2RG</italic></bold></td><td>312863</td><td>Milder allele of SCIDS</td><td>Heterozygotes not affected</td><td>Yes</td><td>Predominantly affects T cells,</td><td><italic>AR</italic></td></tr><tr><td>Tonne–Kalscheurer syndrome</td><td><p>Xq13.2</p><p>74,582,975</p></td><td><p><italic>RLIM</italic></p><p><italic>RFN12</italic></p></td><td>300379</td><td><p>Global developmental delay; ID; subtle facial dysmorphism; multiple congenital anomalies</p><p>autism; severe feeding problems</p></td><td><p>Heterozygotes not affected unless severe</p><p>loss of function</p></td><td>All 4 females with mild skeletal anomalies were extremely skewed (not shown), and normal females also skewed Direction of skewing not shown</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>Thrombocytopenia</bold></p><p><bold>Allelic with Wiskott–Aldrich</bold></p></td><td><p><bold>Xp11.23</bold></p><p><bold>48,683,752</bold></p></td><td><p><bold><italic>WAS</italic></bold></p><p><bold>hypomorphic alleles</bold></p></td><td>313900</td><td>Decreased number of platelets; bleeding tendency</td><td>Rare, presumably due to chance skewing</td><td>Reported as random but results not interpretable</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>Wiskott–Aldrich syndrome</bold></td><td><p><bold>Xp11.23</bold></p><p><bold>48,683,752</bold></p></td><td><p><bold><italic>WAS</italic></bold></p><p><bold>severe loss of function</bold></p></td><td>301000</td><td>Deficiency of B &amp; T cells, leukocytes &amp; thrombocytes</td><td>No affected females</td><td>Yes, severe</td><td>T, B cells &amp; granulocytes</td><td><italic>AR</italic></td></tr><tr><td><p><bold>XLID 1 &amp; 18, 78</bold></p><p><bold>Allelic with</bold></p><p><bold>1Q motif and SEC7 Domain</bold></p><p><bold>18M,19F XLID</bold></p></td><td><p><bold>Xp11.2</bold></p><p><bold>53,225,783</bold></p></td><td><p><bold><italic>IQSEC2</italic></bold></p><p><bold>Nonsense &amp; duplications</bold></p></td><td>300522</td><td>ID nonsyndromic</td><td>Some have learning disabilities</td><td>ND, escapes XI</td><td></td><td></td></tr><tr><td><p><bold>IQ Motif and SEC7 Domain</bold></p><p><bold>18M,19F</bold></p><p><bold>XLID</bold></p><p><bold>allelic with XLIDR 1, 18 and 78</bold></p></td><td><p><bold>Xp11.22</bold></p><p><bold>53,225,783</bold></p></td><td><p><bold><italic>IQSEC2</italic></bold></p><p><bold>(Shapes dendrite morphology) Truncating variants</bold></p></td><td>300522</td><td><p>ID nonsyndromic; 95% have epilepsy</p><p>variants reduce axon length in mice; de novo or maternal</p></td><td><p>Milder ID 70% epilepsy without seizures—all de novo 4/5 affected had random XI</p><p>1 skewed 2 nonaffected carriers had random inactivation</p></td><td><p>No, 1 severely affected female favoring mutant allele</p><p>Human gene escapes XI, but not mouse gene</p></td><td>Blood DNA</td><td><italic>AR</italic></td></tr><tr><td><p>XLID 12</p><p>Also called THOC2 XLID</p></td><td><p>Xq25</p><p>123,600,562</p></td><td><italic>THOC2</italic></td><td>300395</td><td><p>Mild–moderate ID</p><p>Speech delay</p><p>Neurological developmental defect</p></td><td>Heterozygotes not affected</td><td></td><td></td><td></td></tr><tr><td><p>XLID 15</p><p>Cullin Ring</p><p>Cabezas type</p></td><td><p>Xq24</p><p>120,524,588</p></td><td><italic>CUL4B</italic></td><td>300354</td><td>ID (IQ 29–54), short stature macrocephaly, hypogonadism (small testes), tremor, abnormal gait</td><td><p>Rarely mild tremor, tics</p><p>Mice die due to PXI</p><p>Obligate heterozygotes have large hands</p><p>some learning disability</p></td><td>Yes, severe</td><td>WBC</td><td></td></tr><tr><td><bold>XLID Turner</bold></td><td><p><bold>Xp11.22</bold></p><p><bold>53,532,095</bold></p></td><td><p><bold><italic>HUEW1</italic></bold></p><p><bold>E3 ubiquitin ligase</bold></p><p>300697</p><p><bold>Microduplications</bold></p></td><td>309590</td><td><p>Moderate to profound ID, global delay with macrocephaly</p><p>nonsyndromic</p></td><td>Heterozygotes not affected</td><td>Yes &amp; no: severe favoring wild type in some females with microduplications</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td></td><td><p><bold>Xp11.22</bold></p><p><bold>53,532,095</bold></p></td><td><p><bold><italic>HUEW1</italic></bold></p><p><bold>Missense variants</bold></p><p><bold>codes E3 ubiquitin ligase</bold></p></td><td>309590</td><td><p>Moderate to profound</p><p>XLID; short stature; speech pathology; small hands &amp; feet</p></td><td>Heterozygotes not affected</td><td></td><td></td><td></td></tr><tr><td></td><td><p><bold>Xp11.22</bold></p><p><bold>53,532,095</bold></p></td><td><p><bold><italic>HUEW1</italic></bold></p><p><bold>De novo loss of function</bold></p></td><td>309590</td><td>No affected males seen</td><td>Females with dysmorphic XLID; craniostenosis; Chiari malformation</td><td>Severe skewing favoring mutant in affected females</td><td></td><td></td></tr><tr><td>XLID Claes–Jensen</td><td><p>Xp11.22</p><p>53,176,276</p></td><td><p><italic>KDM5C/JARIDC</italic></p><p>314690</p><p>Also, <italic>SMCX</italic></p></td><td>300534</td><td><p>Short stature; microcephaly;</p><p>abnormal facies;</p><p>developmental disability</p></td><td>Milder</td><td>Yes, severe favoring wild type in 4 unaffected heterozygotes</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p>XLID Houge type</p><p>(MRXSHG)</p></td><td>Xp22.2</td><td><p><italic>CNKSR2</italic></p><p>Deletions; frameshifts; truncating variants</p></td><td>301008</td><td>Delayed psychomotor development; poor verbal skills; microcephaly; focal seizures</td><td><p>Mild learning disability or nonaffected</p><p>Speculation that skewed XI prevents severe effects in brain, but not shown, nor is it needed</p></td><td><p>Not shown, but 2 manifesting heterozygotes had 56:43 and 20:80 XI ratios</p><p><italic>CNKSR2</italic> is only expressed in brain tissue</p></td><td>WBC</td><td></td></tr><tr><td>XLID Siderius</td><td><p>Xp11.22</p><p>53,936,679</p></td><td><p><italic>PHF8</italic></p><p>Microdeletion (470 kb)</p></td><td>300263</td><td>ID; abnormal facies; cleft palate/lip</td><td>Heterozygotes not affected</td><td>Yes, severe favoring wild type in unaffected mother,</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>XLID 90</td><td><p>Xq13.1</p><p>70,444,834</p></td><td><p><italic>DLG3</italic></p><p>Truncating</p></td><td>300850</td><td>Moderate to severe nonsyndromic ID</td><td>Heterozygotes are usually not affected</td><td><p>Majority of heterozygotes have random XI Skewing</p><p> influences phenotype</p></td><td></td><td></td></tr><tr><td><bold>XLID 98</bold></td><td><p><bold>Xq13.3</bold></p><p><bold>74,732,855</bold></p></td><td><p><bold><italic>NEXMIF</italic></bold>
<bold>(KIAA2022)</bold></p><p><bold>Hypomorphic loss of function</bold></p></td><td>300524</td><td><p>Severe ID; poor speech postnatal growth retardation</p><p>Strabismus</p></td><td>Usually not affected unless truncating variants (see below)</td><td><p>Normals not studied (one inversion showed skewing)</p><p>1 affected female not skewed (73:27)</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td></td><td><p><bold>Xq13.3</bold></p><p><bold>74,732,855</bold></p></td><td><p><bold><italic>NEXMIF</italic></bold></p><p><bold>(KIAA2022)</bold></p><p><bold>Heterozygous truncating variants—all loss of function</bold></p></td><td>300524</td><td>NA</td><td><p>14 females with</p><p> intractable epilepsy,</p><p>milder ID</p></td><td><p>6/7 had random XI</p><p>1/7 (the most severe) had completely skewed XI favoring mutant cells</p></td><td>WBC</td><td>? Data not shown</td></tr><tr><td><p><bold>XLID 99 Male restricted</bold></p><p><bold>(MRXS99F)</bold></p></td><td><p><bold>Xp11.4</bold></p><p><bold>41,085,419</bold></p></td><td><p><bold><italic>USP9X</italic></bold></p><p><bold>Nontruncating missense variants, no effect on catalytic activity</bold></p></td><td>300919</td><td><p>ID, hypotonia, aggression,</p><p>thin corpus callosum; loss of hippocampal-dependent learning &amp; memory</p></td><td>Female carriers identified and none affected</td><td><p>ND</p><p><italic>USP9X</italic> escapes XI in some tissues, not in others</p></td><td></td><td></td></tr><tr><td><bold>XLID 99 Female restricted</bold></td><td><p><bold>Xp11.4</bold></p><p><bold>41,085,419</bold></p></td><td><p><bold><italic>USP9X</italic></bold></p><p><bold>30072</bold></p><p><bold>Point variants leading to truncation</bold></p><p><bold>De novo loss of function variants</bold></p></td><td>300968</td><td><p>Male lethal</p><p>Truncating variants are lethal in males</p></td><td><p>MR; short; choanal atresia; heart defects; polydactyly;</p><p>hearing loss;</p><p>skin pigmentation (Blaschko)</p></td><td>Affected females may be skewed &gt;90% but test does not show direction; <italic>USP9X</italic> escapes XI in some tissues</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><bold>XLID 102X</bold></td><td><p><bold>Xp11.4</bold></p><p><bold>41,333,307</bold></p></td><td><bold><italic>DDX3X</italic></bold>
<bold>complete loss of function 300160</bold></td><td>300958</td><td>LOF lethal (Decipher shows loss of males)</td><td><p>LOF causes MR, spasticity, ASD</p><p>Heterozygotes with hypomorphic variant are not affected</p></td><td><p>No</p><p><italic>DDX3X</italic> escapes XI</p><p>Homolog on Y</p></td><td></td><td></td></tr><tr><td></td><td><p><bold>Xp11.4</bold></p><p><bold>41,333,307</bold></p></td><td><p><bold><italic>DDX3X</italic></bold></p><p><bold>Hypomorphic variants</bold></p></td><td></td><td>Occasional males have nonsyndromic ID</td><td>No disease</td><td>ND</td><td></td><td></td></tr><tr><td><bold>XLID 106</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,533,103</bold></p></td><td><p><bold><italic>OGT</italic></bold></p><p><bold>Missense</bold></p></td><td>300997</td><td><p>IQ 49–61; facial dysmorphisms</p><p>Mild spastic diplegia plus other congenital abnormalities</p><p>Embryonic lethal (mice)</p></td><td>Females normal but highly skewed X-inactivation</td><td><p>No reference provided</p><p>In mice, if maternal allele mutant then embryonic lethal</p></td><td></td><td></td></tr><tr><td><bold>XLID 106</bold></td><td><p><bold>Xq13.1</bold></p><p><bold>71,533,103</bold></p></td><td><p><bold><italic>OGT</italic></bold></p><p><bold>Missense</bold></p></td><td>300997</td><td>Usually only males</td><td><p>Twin sisters</p><p>XLID plus some facial dimorphisms</p></td><td>Each had 93:07 Direction of skewing not known</td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td>XLID 107</td><td><p>Xq24</p><p>119,538,148</p></td><td><p><italic>Cxorf56</italic></p><p>301012</p><p>Frameshift variant</p></td><td>301013</td><td>5 males: Moderate ID, Long narrow face</td><td><p>Milder</p><p>1 female with no skewing (57%) but nonaffected carriers were skewed</p></td><td><p>Normal</p><p>Significantly skewed (76–93%)</p></td><td>WBC</td><td><italic>AR</italic></td></tr><tr><td><p><bold>XLID Wilson–Turner</bold></p><p><bold>See Cornelia de Lange 5</bold></p></td><td><p><bold>Xq13.2</bold></p><p><bold>72,329,515</bold></p></td><td><p><bold><italic>HDAC8</italic></bold></p><p><bold>Point variants</bold></p></td><td>300269</td><td><p>ID, microcephaly</p><p>craniofacial deformities</p></td><td>Milder</td><td>Yes, extreme</td><td>WBC</td><td><italic>AR</italic></td></tr></tbody></table><table-wrap-foot><p>The X-linked diseases in this table are disorders with available information about heterozygous females. They are listed with their disease name, their X map locus (the location of the gene on the X chromosome, including its 5’ start site, from OMIM). These data are followed by the symbol for the variant gene, the protein that is deficient and the nature of the variant if known. In each case, although the phenotype is variable, the most common one is described. Cell selection favors cells expressing the normal allele, unless otherwise indicated. In all cases chance skewing, that is skewing unrelated to the variant, influences the phenotype. Allelic disorders are indicated in bold.</p><p><italic>AR</italic> androgen receptor, <italic>ASD</italic> autism spectrum disorder, <italic>ID</italic> intellectual deficiency, <italic>LOF</italic> loss of function, <italic>SCIDS</italic> severe combined immunodeficiency syndrome, <italic>XLID</italic> X-linked intellectual deficiency, <italic>WBC</italic> white blood cells.</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec2">
<title>SEX DIFFERENCES ARE DUE TO X-INACTIVATION</title>
<p id="Par5">The sex differences in the effect of X-linked pathologic variants is due to our method of X chromosome dosage compensation, called X-inactivation;<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> humans and most placental mammals compensate for the sex difference in number of X chromosomes (that is, XX females versus XY males) by transcribing only one of the two female X chromosomes. X-inactivation silences all X chromosomes but one; therefore, both males and females have a single active X.<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup></p>
<p id="Par6">For 46 XY males, that X is the only one they have; it always comes from their mother, as fathers contribute their Y chromosome. However, because X chromosomes are silenced in a random fashion, females usually have two kinds of cells in every tissue; those with their maternal X active and those with an active paternal X. Females are protected to a large extent because their two X chromosomes most often differ in genetic content.</p>
<p id="Par7">Sex differences in diseases due to deleterious variants encoded by the X chromosome originate from the sex difference in the expression of the variant allele; if present in male tissues, it is expressed in every cell, but if present in female tissues, the variant is usually expressed in only half the cells (Fig. <xref ref-type="fig" rid="Fig1">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Comparing the effect of a single pathologic variant in females and males.</title><p>Adapted from Fig. 1 of Franco B, Ballabio A. Curr Opin Genet Dev. 2006;16:254–259, with permission of authors. In females: On average, the ratio of the two cell types (expressing normal or variant alleles) is approximately 50:50. However, the ratio may differ because of chance, or a selective disadvantage for cells expressing the variant. Extreme divergence from the 50:50 ratio, known as skewing of XCI, may differ from tissue to tissue, and among individuals influencing the severity of the phenotype. Cell selection usually takes place only in cells which express the variant and which do not receive the essential gene products from the normal cells that make them. In males<underline>:</underline> an X-linked variant is expressed in every cell. The exceptions are males with somatic mosaicism: like females, mosaic males will express both variant and normal allele, and the phenotype depends on the admixture of variant and normal cells.</p></caption><graphic id="d30e6472" xlink:href="41436_2020_779_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec3">
<title>FEMALES ARE MOSAICS</title>
<p id="Par8">A woman is less susceptible to the pathogenic variants in genes on her active X chromosome because the variant is not expressed in all her cells.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup></p>
</sec>
<sec id="Sec4">
<title>FEMALES CAN AMELIORATE THE EFFECTS OF PATHOGENIC VARIANTS</title>
<p id="Par9">Most women do not manifest X-linked disorders because (1) they are not homozygous for the pathogenic variant, and (2) their variant cells (those expressing the deleterious allele) receive sufficient gene product to carry out the essential metabolic function from the cells that transcribe the normal allele.</p>
<p id="Par10">The crucial protein is provided in one of two ways. Either the cells that can make it transfer it to the deficient cells, or, if this cell-to-cell transport does not take place, the lack of functional protein may cause the deficient cells to divide less efficiently, and so they are eventually overgrown by the cells that make the normal protein. Yet, in various tissues, cells differ in their capacity to transfer gene products and so there may be differences within body tissues in the ability of the normal cell to share, or the abnormal cell to survive<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> (Fig. <xref ref-type="fig" rid="Fig1">1</xref>, Table <xref ref-type="table" rid="Tab1">1</xref>).</p>
</sec>
<sec id="Sec5">
<title>FEMALES ALMOST ALWAYS HAVE LESS SEVERE MANIFESTATIONS OF X-LINKED DISEASES</title>
<p id="Par11">For most X-linked deleterious variants, the manifestations are less severe in females than males. The mix of normal and abnormal cells moderates females' disease. Yet, there are disorders in which the variant is so lethal that most males with severe deficiency of the gene product die in utero. Because the only survivors are females or mosaic males, who also have a mix of variant and normal cells, they are the ones with nonlethal manifestation of the disorder. X-linked diseases, such as incontinentia pigmenti, or orofacial digital syndrome type 1, occur only in females or mosaic males.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup></p>
</sec>
<sec id="Sec6">
<title>SOME FEMALES ARE MANIFESTING HETEROZYGOTES</title>
<p id="Par12">Many factors determine if a heterozygote manifests her mosaic variant. Our knowledge of the effect of second variants of genes in related pathways on the ultimate phenotype is meager, but suggests that we need to be aware of the potential effect of other relevant genes on any variant. Although Table <xref ref-type="table" rid="Tab1">1</xref> includes only one known instance of digenic X variants (Dent disease 2), one expects there will be more. The effect of digenic variants leading to Dent disease are ameliorated in the heterozygote, who carries both variants on the same X chromosome, as these abnormal cells are strongly disfavored (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> In this case, heterozygotes are much less severely affected than hemizygous males because of the strong cell selection against cells expressing the two variants simultaneously.</p>
</sec>
<sec id="Sec7">
<title>EFFECT OF SEX AND X-INACTIVATION ON PHENOTYPE IN X-LINKED DISORDERS</title>
<p id="Par13">As I learn about why some heterozygotes express their variants, yet others with the same variant do not, I more fully appreciate the nuances of disease processes and the intricacy of the interdependence between the type of cell, its response to abnormal gene products, and the nature of the disease variant. Table <xref ref-type="table" rid="Tab1">1</xref> shows the effect of pathogenic variants of X-linked genes in males and females. For almost all of the disorders listed, females have less severe clinical manifestations. Table <xref ref-type="table" rid="Tab1">1</xref> also documents the variables that determine if an X chromosomal variant is manifested or not, that is, if products are shared or if normal cells have a selective advantage. The severity of the phenotype is most often attributable to the nature of the variant. Does it completely eliminate the gene’s function, or does it allow some gene product to be produced? Variants that disable an essential protein completely are more often seen in females, as males whose only gene is nonfunctional are lost in utero, unless other genes can substitute for it. On the other hand, variants with some residual function may affect only males. In both cases, the female phenotype is less severe, as she has some normal cells that carry out the essential function.</p>
</sec>
<sec id="Sec8">
<title>EFFECT OF SHARING GENE PRODUCT BETWEEN CELLS</title>
<p id="Par14">Because it is largely unknown, Table <xref ref-type="table" rid="Tab1">1</xref> does not include the quantity of gene product that must be provided to a cell to replace that lost through a variant. In most cases 50% activity is more than enough, and for many genes, even smaller amounts of product will suffice. This readily explains why many X-linked disorders never affect women. For example, less than 5% of the enzyme HPRT can alter the phenotype from severe hyperuricemia, seen in Lesch–Nyhan males, to gout. Lesch–Nyhan heterozygotes rarely express any features of the syndrome, including gout. In most of her tissues the product of the HPRT reaction, inosinic acid, is transferred from her cells that synthesize it, to those that cannot, through gap junctions, present in all cells of the body except blood cells.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup></p>
<p id="Par15">Cell sharing also occurs in women who are heterozygous for variants causig X-linked lysosomal diseases. Lysosomes contain many enzymes that break down proteins and lipids. Variants in the genes that encode these enzymes cause diseases by the accumulation of undegraded material within the lysosomes of affected individuals. Fortunately, the deficient cells of the heterozygote can take up the enzyme secreted by the normal cells through a process called endocytosis. Therefore, potential manifestations in carriers of variants of lysosomal enzymes encoded by the X chromosome are generally ameliorated by the transfer of these enzymes from the cells that can make them to those that cannot.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></p>
</sec>
<sec id="Sec9">
<title>EFFECT OF CELL SELECTION IN MOSAIC FEMALES</title>
<p id="Par16">Because they lack gap junctions, the leukocytes from Lesch–Nyhan heterozygotes do not receive the inosinic acid made by their normal counterparts. Fortunately, the lack of inosinic acid slows the rate of cell division; the normal cells (because the variant is on their inactive X) eventually replace the deficient ones. As a consequence, heterozygous mothers and sisters of Lesch–Nyhan males have only normal blood cells, and in other tissues, their mutant cells share the gene products provided by their normal cells.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> It takes about ten years for all their abnormal red cells to be replaced<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> because in this case, the selective advantage of the normal allele is relatively small.</p>
<p id="Par17">The rate of loss of deficient cells can be slow or fast depending on the degree to which the variant is disadvantageous. When selection is intense, that is, when it severely disfavors the cells that express the variant, heterozygous females benefit, as they rapidly lose all their mutant cells. Sometimes the loss of variant cells occurs so early that abnormal cells may never enter a tissue. In cases of immunodeficiencies, like Wiskott–Aldrich syndrome, the growth disadvantage is immediate; the mutant B cell precursors never leave the bone marrow (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
<p id="Par18">Unfortunately, sometimes it is the variant cell that has the selective advantage. For reasons not yet understood, heterozygotes with the variant causing adrenoleukodystrophy slowly lose their population of wild type cells.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> Therefore, as they age, they usually manifest some symptoms of the disease. Adrenoleukodystrophy is the only known X-linked disease where the variant allele has a selective advantage. X-linked variants that slow the growth of the expressing cells usually protect females from manifesting them. If one examines the cells from these heterozygotes, one sees highly skewed patterns of X-inactivation in the expressing tissues: eventually, the X with the variant will always be silent (that is, always on the inactive X). Females carrying pathologic variants that produce X-linked mental retardation often have X-inactivation patterns that are highly skewed favoring expression of the wild type gene, protecting them from ill effects of their variant.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> In such women, the cells that express the variant gene are disfavored.</p>
</sec>
<sec id="Sec10">
<title>MANIFESTING HETEROZYGOTES</title>
<p id="Par19">With so many mechanisms available to protect females with an X-linked pathologic variant, one wonders why some heterozygotes manifest any symptoms of a disease. As mentioned previously, if the variant is so functionless that it is lethal to fetal or newborn males, then females with a single mutant allele are the only ones that can have the disease. As Table <xref ref-type="table" rid="Tab1">1</xref> indicates, the severity of the variant can determine if females express the variant or not.</p>
<p id="Par20">Occasionally, females are the ones to manifest a disease because the variant allele interacts with the normal one, undergoing a process called cellular interference. The most well defined example of this is the craniofrontonasal syndrome, caused by a deficiency of Ephrin-B1 (<italic>EFNB1</italic>).<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> Other members of the ephrin family of proteins can substitute for a deficiency of <italic>EFNB1</italic> in males with the deleterious variant, and as a result, they have minimal clinical symptoms. Heterozygotes, however, have a mixture of mutant and wild type cells; for reasons not yet understood, it seems that such mixtures do not permit ephrin substitutes, and consequently, females have a deficiency more severe than that in males, who can substitute one ephrin for another. It is heterozygosity, not the complete loss of function, that produces the severe disorder. It is the patchwork or mosaic loss of <italic>EFNB1</italic> that disturbs tissue boundary formation at the developing coronal suture. Several forms of infantile epilepsy also show similar cellular interference, but fortunately no other examples are known.</p>
<p id="Par21">Yet, there are females who express an X-linked pathogenic variant, even though most carriers of pathogenic variants in similar genes do not. For example, females with Fabry disease, caused by lack of the lysosomal enzyme ɑ-galactosidase may have some of the clinical symptoms seen in affected males, whereas carriers of a variant in a gene encoding another lysosomal enzyme, iduronic sulfatase, rarely have any clinical symptoms associated with Hunter syndrome.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> Both enzymes are made in the lysosomes, and can be transported from the lysosomes of one cell to those of another cell. The two lysosomal disorders differ because iduronate sulfatase is taken up by cells better than the low uptake enzyme, ɑ-galactosidase.<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> This difference in the ability of the lysosome to take up a product is responsible for normal Hunter heterozygotes and manifesting Fabry heterozygotes.</p>
</sec>
<sec id="Sec11">
<title>OTHER DETERMINANTS OF MANIFESTING HETEROZYGOTES</title>
<p id="Par22">One wonders why some heterozygotes express disorders that do not affect most of the others with the same variant. Some females manifest their X-linked variant because it is overexpressed; their variant is expressed in more than half their cells because of skewing in the proportions of normal and abnormal cells. Although random inactivation usually means that 34–68% of heterozygous cells are abnormal,<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> a few heterozygotes have more than 90% variant cells. Such females manifest the disorder because their wild type allele is not expressed sufficiently. These manifesting heterozygotes are often reported in medical journals because they are affected with a disease that usually occurs only in males. In some cases, a chance chromosome translocation or deletion is responsible for the skew, as such abnormal X chromosomes often influence the direction of skewing. X/autosome translocation chromosomes are responsible for the rare females afflicted with Duchenne muscular dystrophy.<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> Maternal isodisomy,<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> early onset monozygotic twinning (known to promote skewing<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>), and other extreme skewing of X-inactivation<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> have also been responsible for manifesting heterozygotes (Table <xref ref-type="table" rid="Tab2">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Factors influencing expression of X-linked variant in females.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variant</th><th></th><th colspan="4">X-inactivation</th><th colspan="2">Outcome<sup>a</sup></th></tr><tr><th>Number of mutant alleles</th><th>Strength of variant</th><th>Random</th><th>Skewed To variant<sup>b</sup></th><th>Skewed To wild type<sup>c</sup></th><th>Escape allele<sup>d</sup></th><th>Males</th><th>Females</th></tr></thead><tbody><tr><td>Biallelic (rare)</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td></td><td>Affected</td><td>Equally affected as male</td></tr><tr><td></td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>+</td><td>Affected</td><td>Equally affected or worse than male</td></tr><tr><td>Monoallelic</td><td>Mild to moderate</td><td><bold>+</bold></td><td></td><td></td><td></td><td>Affected</td><td>Less severe or no abnormalities</td></tr><tr><td></td><td>Mild to moderate</td><td></td><td><bold>+</bold></td><td></td><td></td><td>Affected</td><td>Equally affected</td></tr><tr><td></td><td>Mild to moderate</td><td></td><td></td><td></td><td><bold>+</bold></td><td>Affected</td><td>Less or more severe</td></tr><tr><td></td><td>Severe</td><td><bold>+</bold></td><td></td><td></td><td></td><td>Fetal lethal</td><td>Express variant</td></tr><tr><td></td><td>Severe</td><td></td><td></td><td><bold>+</bold></td><td></td><td>Fetal lethal</td><td>Less severe</td></tr><tr><td></td><td>Severe</td><td></td><td><bold>+</bold></td><td></td><td></td><td>Fetal lethal</td><td>Severe or lethal</td></tr><tr><td></td><td>Severe</td><td></td><td></td><td></td><td><bold>+</bold></td><td>Fetal lethal</td><td>Less or more severe</td></tr><tr><td></td><td>X/A translocation</td><td></td><td></td><td><bold>+</bold></td><td></td><td>Affected</td><td>Less severe</td></tr><tr><td></td><td>X/A translocation</td><td></td><td><bold>+</bold></td><td></td><td></td><td>Affected</td><td>More severe</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Male phenotype is given; female phenotype is given relative to male.</p><p><sup>b</sup>Variant allele is on the active X.</p><p><sup>c</sup>Normal allele is on the active X.</p><p><sup>d</sup>Allele is also expressed to a small extent from the inactive X.</p></table-wrap-foot></table-wrap></p>
<p id="Par23">Although some skewing may be attributable to abnormalities of the <italic>XIST</italic> locus,<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> such variants occur only rarely. If one <italic>XIST</italic> allele loses function, than that allele is always on the active X. Minor loss of function variants of <italic>XIST</italic> may lead to some skew,<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> but few have been reported. Cell selection and random skewing are the most frequent causes of nonrandom X-inactivation. Random skewing frequently occurs because of events surrounding twinning, and confined placental mosaicism.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> Often skewing is due to the randomness of the inactivation process, which is stochastic and therefore due to chance. Ten percent of females are &gt;2 standard deviations from the mean of 50%.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup></p>
<p id="Par24">Stochastic skewing that favors cells that inactivate the normal <italic>WDR45</italic> allele is responsible for neurodegeneration seen in the rare female infants who manifest the X-linked pathologic variant (<italic>NBIA5</italic>), because their brains accumulate iron. If this disorder is caused by a truncating variant, only mosaic males, or females who are highly skewed favoring the normal allele, manifest the disease, as all other males and females with the variant die in utero. Affected females with hypomorphic variants often skew favoring the mutant allele (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
</sec>
<sec id="Sec12">
<title>DEGREE OF CELL SELECTION IS DETERMINED BY THE VARIANT</title>
<p id="Par25">The X-linked form of Kabuki syndrome is caused either by point variants or deletions in <italic>KDM6A</italic>. Females with point variants often have Kabuki syndrome, whereas those with the larger deletions silence the X carrying the deletion; hence, they have less severe manifestations.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup></p>
<p id="Par26">Only a rare heterozygote with a variant in the <italic>PLP1</italic> gene has symptoms of the myelin leukodystrophy associated with Pelizaeus–Merzbacher syndrome, and she invariably shows chance skewing favoring the mutant cells.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> In addition, during the central nervous system (CNS) development of heterozygotes, the oligodendrocytes with severe <italic>PLP1</italic> disease alleles are negatively selected (apoptosis) in favor of wild type cells, resulting in skewed X-inactivation that is cell type specific.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
</sec>
<sec id="Sec13">
<title>ESCAPE GENES INFLUENCE PHENOTYPE</title>
<p id="Par27">Another factor that influences the clinical manifestations of X-linked variants in heterozygotes is the partial expression of genes from the inactive X chromosome.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> In addition to those genes in the pseudoautosomal region that are expressed on both sex chromosomes, more than 100 genes on the human X chromosome are expressed not only from the active X, but also to some extent from the silent X.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> They are referred to as escape genes. In fact, such genes do not really escape silencing, as they function to some extent, usually producing 10–30% of the level of transcripts made by the homologous allele on the active X. Yet, this little extra expression of a gene does influence phenotype. For example, male fetuses with pathologic variants causing orofacial digital syndrome all die in utero, unless they have a second X chromosome (i.e., Klinefelter syndrome); human females survive birth and die in their forties, usually from renal failure. However, female mice with the same variant outlive males by only several weeks as they die as neonates due to their polycystic kidneys. The important species difference is that humans, but not mice, partially express the <italic>OFD1</italic> gene from their inactive X.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> This little extra gene activity is responsible for the difference in age of death of females of the two species. A little extra gene product from the inactive X can ameliorate the effects of an X-linked variant (see Table <xref ref-type="table" rid="Tab2">2</xref>).</p>
<p id="Par28">The extra product may not be available in every tissue, as there are tissue-specific differences in the expression of escape genes. In several females with a <italic>USP9X</italic> variant, pigment changes along the Blaschko lines and body asymmetry were observed, which is probably related to differential escape from X-inactivation between tissues<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and Table <xref ref-type="table" rid="Tab1">1</xref>.</p>
<p id="Par29">Yet, a little extra activity from the inactive X is not always helpful. It seems that expression of the Toll-like receptors on the inactive X is partly responsible for the impressive sex differences in some cases of autoimmune diseases like Lupus and Sjogren disease.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> Toll-like receptors, encoded by the X chromosome, are signaling pattern recognition receptors that are an integral part of innate immunity. The little extra activity may provide females with better protection against infectious agents, but it may make them more susceptible to autoimmunity. Such disorders are nine times as frequent in females than males and are also increased in Klinefelter XXY males, whereas as Turner females, even those taking estrogens, have the same risk as XY males. It is now thought that the excess manifestations of autoimmune disease in women are due to a complex of issues. Studies in mice show that increasing the expression of the X-linked Toll-like receptors in susceptible mice increases the expression of the autoimmune disorder.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> It has not yet been shown that affected females and Klinefelter males have greater expression of their Toll-like receptors than those women and XXY males who do not have the disorder.</p>
<p id="Par30">Other relevant X-linked genes with potential to influence autoimmunity and that escape X-inactivation include <italic>CXCR3</italic>,<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>
<italic>KDM6A</italic>,<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and <italic>CXorf21</italic>, which has been shown to be more highly expressed in women and Klinefelter males than in normal men.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> In addition, the expression of <italic>XIST</italic> from the inactive X in lymphocytes differs significantly from that of other cells as the <italic>XIST</italic> RNA cloud is dispersed, leading to poorer Barr body formation.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> No doubt, it is the interaction of several factors that is responsible for the high incidence of autoimmunity associated with having two X chromosomes.</p>
</sec>
<sec id="Sec14">
<title>DIFFERENT DISORDERS FROM THE SAME GENE</title>
<p id="Par31">What is increasingly apparent is that variants in a single gene can lead to differently named disorders, because of the specific effect of the variant on production of the gene product. Before variants were identified, diseases were classified by their phenotypes and named by the physician who reported the disease, based on its symptoms. Now, we know that many different phenotypic disorders may be due to variations in the same gene; their effect in the heterozygote reflects the severity of the variant, which has influenced the naming of the disorder. Table <xref ref-type="table" rid="Tab1">1</xref> shows some of these allelic disorders (in bold). Yet, in most cases, no matter the severity of the disease in males, the heterozygous female is better off than the hemizygous male.</p>
<p id="Par32">Examples of allelic disorders are the different variants in the IKBKG gene, which can cause incontinentia pigmenti (IP) if dysfunction is severe, ectodermal dysplasia if dysfunction is moderate, and immunodeficiency 33 if it is mild. When the pathologic variant is severe (like IP), females may be the only ones that manifest the disorder, as males die in utero. On the other hand, when it is moderate, or mild (like immunodeficiency 33), women may completely escape its pathologic effects (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
<p id="Par33">Another set of allelic disorders is caused by variants in the <italic>PRPS1</italic> gene, responsible for syndromes of deafness (missense variant leading to reduced expression), gout (gain of function variant), and Charcot–Marie–Tooth disease (more severe reduction of expression), depending on the severity of the specific variant. Again, the heterozygous female always has a less severe phenotype than the hemizygous male. When the male is deaf, the female has high range hearing loss; when he has gout, she has no manifestations. However, when he has optic atrophy and neuropathies, she has much milder manifestations, or none at all (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
<p id="Par34">There is a spectrum of allelic disorders caused by different variants in the filamin A gene; again females are always less affected than males with the same deleterious variants, and are the only ones affected with Melnick–Needles syndrome, because it is lethal in males (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
<p id="Par35">There are also allelic disorders caused by different variations in the <italic>MECP2</italic> gene. Rett syndrome results when the gene has a deletion or substitution variant that decreases its function; the loss of function causes a disorder that is usually lethal to unborn males, so that generally only females survive to manifest the disease. However, when the same gene is duplicated (Lubs X-linked intellectual disability [XLID], Table <xref ref-type="table" rid="Tab1">1</xref>), the increased function permits males to survive and manifest the disorder, whereas the gene duplication provides the normal allele a selective advantage, so that females escape all manifestations, as the duplicated gene is always on the inactive X (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></p>
<p id="Par36">Another impressive example of the effect of allelic disorders on sex differences in expression of the disease are variants in the <italic>USP9X</italic> gene (Table <xref ref-type="table" rid="Tab1">1</xref>).<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> As point variants leading to truncation are lethal for the male fetus, the manifestations are confined to females. On the other hand, less severe nontruncated variants in the same gene cause hippocampal related mental retardation, hypotonia, and aggression in males, whereas carrier females have no abnormalities.</p>
</sec>
<sec id="Sec15">
<title>MANY X-LINKED GENES ARE ASSOCIATED WITH INTELLECTUAL DEFICIENCY</title>
<p id="Par37">The proportion of X-linked variants causing intellectual deficits is striking. In addition to the many X-linked variants whose phenotypes include intellectual disability, there are many disorders that are <italic>specifically</italic> associated with X-linked intellectual deficiency, both syndromic and nonsyndromic; these are listed in OMIM as XLID followed by a number from 1 to 107. These disorders map from the telomere of the short arm to the last band on the long arm of the X. Although the role of the gene whose variant leads to the disorder is not always well defined, the genes responsible for X-linked intellectual disability are involved in many pathways. It seems that intelligence is the sum total of how all our genes are functioning. Malfunctions of genes in many pathways can interfere with intellectual capabilities. Extreme skewing of X-inactivation is frequently seen with XLID variants that permit male survival, and the variant is always found on the inactive X in females; consequently, they have normal intellectual function. Apparently, such disease-producing variants are toxic for expressing cells.</p>
</sec>
<sec id="Sec16">
<title>SUMMARY</title>
<p id="Par38">Being mosaic for the function of their X-linked genes generally ameliorates the expression of X-linked deleterious variants in females. X-inactivation provides the opportunity to share gene products. If this is not possible, then cell selection may eliminate variant cells. Many of these variants affect intellectual ability. Females usually manifest their X-linked pathologic variants, if both alleles are disease variants, or if males with the same pathogenic variants are lost in utero. X-inactivation provides an enormous advantage to females with deleterious X-linked variants, most often enabling them to avoid disease manifestations, including intellectual disability, that affect males. Fortunately, chance skewing that favors mutant alleles is relatively rare (5%) in survivors. The female advantage is reflected by the 20% greater death rate for males at every stage postimplantation, until the age of &gt;75 years, when more females die because there are fewer male survivors.<sup><xref ref-type="bibr" rid="CR41">41</xref></sup></p>
<p id="Par39">The females susceptible to X-linked diseases are those who have more than one copy of a pathologic variant, or a relevant second variant, or a variant in an essential gene that does not permit males to survive (Table <xref ref-type="table" rid="Tab2">2</xref>). Females are also susceptible to chance skewing favoring the mutant allele, or the effects of X chromosomal aberrations (i.e., translocations) and monozygotic twinning on inducing unfavorable skewing.<sup><xref ref-type="bibr" rid="CR42">42</xref></sup></p>
<p id="Par40">The fact that more males are born than females (1.05:1) is also likely to be attributable to X-inactivation. In this case, preimplantation females are lost because of their greater dosage sensitivity in <italic>maintaining</italic> an active X.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> But if XX individuals successfully establish X-inactivation while in utero, then throughout their lifetime, they will benefit from the cellular mosaicism it produces.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>I am grateful to readers Haig Kazazian, Hans Bjornsson, and Steven Salzberg in our McKusick-Nathans Department of Genetic Medicine for their helpful comments. Thanks also to Cate Kiefe for her adaptation of Fig. <xref ref-type="fig" rid="Fig1">1</xref> from <italic>Current Opinion in Genetics &amp; Development</italic> 2006;16:254–259, and to its authors, Brunella Franco and Andrea Ballabio, for permission to use it.</p>
</ack>
<notes id="FPar1" notes-type="COI-statement">
<title>Disclosure</title>
<p id="Par41">B.R.M. declares no conflicts of interest.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rivaud</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>van Veen</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease</article-title>
<source/>Biol Sex Differ
          <year>2019</year>
<volume>10</volume>
<fpage>7</fpage>
<pub-id pub-id-type="doi">10.1186/s13293-019-0223-0</pub-id>
<pub-id pub-id-type="pmid">30717770</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natri</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buetow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Trumble</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The pregnancy pickle: evolved immune compensation due to pregnancy underlies sex differences in human diseases</article-title>
<source/>Trends Genet
          <year>2019</year>
<volume>35</volume>
<fpage>478</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2019.04.008</pub-id>
<pub-id pub-id-type="pmid">31200807</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nuzzi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Scalabrin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Becco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Panzica</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Sex hormones and optic nerve disorders: a review</article-title>
<source/>Front Neurosci
          <year>2019</year>
<volume>13</volume>
<fpage>57</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2019.00057</pub-id>
<pub-id pub-id-type="pmid">30804741</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Salameh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chanson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bucher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ringa</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Becquemont</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Cardiovascular disease in type 2 diabetes: a review of sex-related differences in predisposition and prevention</article-title>
<source/>Mayo Clin Proc
          <year>2019</year>
<volume>94</volume>
<fpage>287</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1016/j.mayocp.2018.08.007</pub-id>
<pub-id pub-id-type="pmid">30711127</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gogos</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link?</article-title>
<source/>Br J Pharmacol
          <year>2019</year>
<volume>176</volume>
<fpage>4119</fpage>
<lpage>4135</lpage>
<pub-id pub-id-type="doi">10.1111/bph.14584</pub-id>
<pub-id pub-id-type="pmid">30658014</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>The role of X inactivation and cellular mosaicism in women’s health and sex-specific diseases</article-title>
<source/>JAMA.
          <year>2006</year>
<volume>295</volume>
<fpage>1428</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="doi">10.1001/jama.295.12.1428</pub-id>
<pub-id pub-id-type="pmid">16551715</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<mixed-citation publication-type="other">National Center for Biotechnology Information. Gene. 2019. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene">https://www.ncbi.nlm.nih.gov/gene</ext-link>.</mixed-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<mixed-citation publication-type="other">OMIM. X-linked diseases. 2019. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/omim/?term=X+linked+diseases">https://www.ncbi.nlm.nih.gov/omim/?term=X+linked+diseases</ext-link>.</mixed-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyon</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Sex chromatin and gene action in the mammalian X-chromosome</article-title>
<source/>Am J Hum Genet
          <year>1962</year>
<volume>14</volume>
<fpage>135</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">14467629</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Choosing the active X: the human version of X inactivation</article-title>
<source/>Trends Genet.
          <year>2017</year>
<volume>33</volume>
<fpage>899</fpage>
<lpage>909</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2017.09.005</pub-id>
<pub-id pub-id-type="pmid">28988701</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Beer</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bjornsson</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Embryonic loss of human females with partial trisomy 19 identifies region critical for the single active X</article-title>
<source/>PLoS One
          <year>2017</year>
<volume>12</volume>
<fpage>e0170403</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0170403</pub-id>
<pub-id pub-id-type="pmid">28403217</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
</person-group>
<source/>Females are mosaics: X inactivation and sex differences in disease.
          <year>2014</year>
<edition>2nd ed.</edition>
<publisher-loc>New York</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franco</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ballabio</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>X-inactivation and human disease: X-linked dominant male-lethal disorders</article-title>
<source/>Curr Opin Genet Dev
          <year>2006</year>
<volume>16</volume>
<fpage>254</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2006.04.012</pub-id>
<pub-id pub-id-type="pmid">16650755</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cox</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Balis</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Dancis</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Evidence for transfer of enzyme product as the basis of metabolic cooperation between tissue culture fibroblasts of Lesch–Nyhan disease and normal cells</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1970</year>
<volume>67</volume>
<fpage>1573</fpage>
<lpage>1579</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.67.3.1573</pub-id>
<pub-id pub-id-type="pmid">5274481</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Sprenkle</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Liebaers</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Neufeld</surname>
<given-names>EF</given-names>
</name>
</person-group>
<article-title>X-linked Hunter syndrome: the heterozygous phenotype in cell culture</article-title>
<source/>Am J Hum Genet
          <year>1977</year>
<volume>29</volume>
<fpage>448</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="pmid">409283</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>Studies of skin fibroblasts from 10 families with HGPRT deficiency, with reference in X-chromosomal inactivation</article-title>
<source/>Am J Hum Genet
          <year>1971</year>
<volume>23</volume>
<fpage>199</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">5092480</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
</person-group>
<article-title>X-linked hypoxanthine-guanine phosphoribosyl transferase deficiency: detection of heterozygotes by selective medium</article-title>
<source/>Biochem Genet.
          <year>1970</year>
<volume>4</volume>
<fpage>377</fpage>
<lpage>383</lpage>
<pub-id pub-id-type="doi">10.1007/BF00485754</pub-id>
<pub-id pub-id-type="pmid">5477231</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Migeon</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Moser</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Axelman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sillence</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Norum</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Adrenoleukodystrophy: evidence for X linkage, inactivation, and selection favoring the mutant allele in heterozygous cells</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1981</year>
<volume>78</volume>
<fpage>5066</fpage>
<lpage>5070</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.78.8.5066</pub-id>
<pub-id pub-id-type="pmid">6795626</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plenge</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Lubs</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Willard</surname>
<given-names>HF</given-names>
</name>
</person-group>
<article-title>Skewed X-chromosome inactivation is a common feature of X-linked mental retardation disorders</article-title>
<source/>Am J Hum Genet
          <year>2002</year>
<volume>71</volume>
<fpage>168</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="doi">10.1086/341123</pub-id>
<pub-id pub-id-type="pmid">12068376</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Twigg</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Babbs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van den Elzen</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Goriely</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McGowan</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cellular interference in craniofrontonasal syndrome: males mosaic for mutations in the X-linked EFNB1 gene are more severely affected than true hemizygotes</article-title>
<source/>Hum Mol Genet
          <year>2013</year>
<volume>22</volume>
<fpage>1654</fpage>
<lpage>1662</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddt015</pub-id>
<pub-id pub-id-type="pmid">23335590</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fratantoni</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Neufeld</surname>
<given-names>EF</given-names>
</name>
</person-group>
<article-title>Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts</article-title>
<source/>Science.
          <year>1968</year>
<volume>162</volume>
<fpage>570</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1126/science.162.3853.570</pub-id>
<pub-id pub-id-type="pmid">4236721</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>LLC</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Giugliani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>IVD</given-names>
</name>
</person-group>
<article-title>Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review</article-title>
<source/>Orphanet J Rare Dis
          <year>2010</year>
<volume>5</volume>
<fpage>14.</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-5-14</pub-id>
<pub-id pub-id-type="pmid">20509947</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Why are females with Fabry disease affected?</article-title>
<source/>Mol Genet Metab Rep
          <year>2019</year>
<volume>21</volume>
<fpage>100529</fpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2019.100529</pub-id>
<pub-id pub-id-type="pmid">31687338</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bart</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Duchenne muscular dystrophy (DMD) in a female with an X/autosome translocation: further evidence that the DMD locus is at Xp21</article-title>
<source/>Am J Hum Genet
          <year>1981</year>
<volume>33</volume>
<fpage>513</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="pmid">7258185</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Janas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Toth-Fejel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Wolford</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Popovich</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>Uniparental disomy of the entire X chromosome in a female with Duchenne muscular dystrophy</article-title>
<source/>Am J Hum Genet
          <year>1997</year>
<volume>60</volume>
<fpage>160</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="pmid">8981959</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Povey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>West</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Duchenne muscular dystrophy in one of monozygotic twin girls</article-title>
<source/>J Med Genet
          <year>1986</year>
<volume>23</volume>
<fpage>494</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.23.6.494</pub-id>
<pub-id pub-id-type="pmid">2879922</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trejo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Derom</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vlietinck</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ollier</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Silman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ebers</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>X chromosome inactivation patterns correlate with fetal-placental anatomy in monozygotic twin pairs: implications for immune relatedness and concordance for autoimmunity</article-title>
<source/>Mol Med.
          <year>1994</year>
<volume>1</volume>
<fpage>62</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1007/BF03403532</pub-id>
<pub-id pub-id-type="pmid">8790602</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soltanzadeh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Friez</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>von Niederhausern</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gurvich</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Swoboda</surname>
<given-names>KJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical and genetic characterization of manifesting carriers of DMD mutations</article-title>
<source/>Neuromuscul Disord.
          <year>2010</year>
<volume>20</volume>
<fpage>499</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="doi">10.1016/j.nmd.2010.05.010</pub-id>
<pub-id pub-id-type="pmid">20630757</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plenge</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Hendrich</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Willard</surname>
<given-names>HF</given-names>
</name>
</person-group>
<article-title>A mutation in the XIST promoter in a family with nonrandom X chromosome inactivation</article-title>
<source/>Am J Hum Genet
          <year>1995</year>
<volume>57S</volume>
<fpage>A30</fpage>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lau</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Penaherrera</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Langlois</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kalousek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Skewed X-chromosome inacctivation is common in fetuses or newborns associated with confined placental mosaicism</article-title>
<source/>Am J Hum Genet
          <year>1997</year>
<volume>61</volume>
<fpage>1353</fpage>
<lpage>1361</lpage>
<pub-id pub-id-type="doi">10.1086/301651</pub-id>
<pub-id pub-id-type="pmid">9399909</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lederer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Grisart</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Digilio</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Benoit</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Crespin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ghariani</surname>
<given-names>SC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome</article-title>
<source/>Am J Hum Genet
          <year>2012</year>
<volume>90</volume>
<fpage>119</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2011.11.021</pub-id>
<pub-id pub-id-type="pmid">22197486</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scala</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Traverso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Capra</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vari</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Severino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grossi</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pelizaeus–Merzbacher disease due to PLP1 frameshift mutation in a female with nonrandom skewed X-chromosome inactivation</article-title>
<source/>Neuropediatrics.
          <year>2019</year>
<volume>50</volume>
<fpage>268</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1055/s-0039-1688954</pub-id>
<pub-id pub-id-type="pmid">31137068</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Disteche</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Escape from X inactivation in humans and mouse</article-title>
<source/>Trends Genet
          <year>1995</year>
<volume>11</volume>
<fpage>17</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/S0168-9525(00)88981-7</pub-id>
<pub-id pub-id-type="pmid">7900190</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balaton</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Dixon-McDougall</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Peeters</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>The eXceptional nature of the X chromosome</article-title>
<source/>Hum Mol Genet
          <year>2018</year>
<volume>27</volume>
<fpage>R242</fpage>
<lpage>R9</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddy148</pub-id>
<pub-id pub-id-type="pmid">29701779</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reijnders</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Zachariadis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Latour</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jolly</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo loss-of-function mutations in USP9X cause a female-specific recognizable syndrome with developmental delay and congenital malformations</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>98</volume>
<fpage>373</fpage>
<lpage>381</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.12.015</pub-id>
<pub-id pub-id-type="pmid">26833328</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syrett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Anguera</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>When the balance is broken: X-linked gene dosage from two X chromosomes and female-biased autoimmunity</article-title>
<source/>J Leukocyte Biol
          <year>2019</year>
<volume>106</volume>
<fpage>919</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="doi">10.1002/JLB.6RI0319-094R</pub-id>
<pub-id pub-id-type="pmid">31125996</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oghumu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Varikuti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stock</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Volpedo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Saljoughian</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Terrazas</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cutting edge: CXCR3 escapes X chromosome inactivation in T cells during infection: potential implications for sex differences in immune responses</article-title>
<source/>J Immunol
          <year>2019</year>
<volume>203</volume>
<fpage>789</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1800931</pub-id>
<pub-id pub-id-type="pmid">31253729</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuichiro</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Golden</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Noriko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Matsukawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The X-linked histone demethylase Kdm6a in CD4+T lymphocytes modulates autoimmunity</article-title>
<source/>J Clin Invest
          <year>2019</year>
<volume>130</volume>
<fpage>3852</fpage>
<lpage>3863</lpage>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Koelsch</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Kurien</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Harley</surname>
<given-names>ITW</given-names>
</name>
<name>
<surname>Wren</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Harley</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization of cxorf21 provides molecular insight into female-bias immune response in SLE pathogenesis</article-title>
<source/>Front Immunol.
          <year>2019</year>
<volume>10</volume>
<fpage>2160</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.02160</pub-id>
<pub-id pub-id-type="pmid">31695690</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syrett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Paneru</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sandoval-Heglund</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sindhava</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases</article-title>
<source/>JCI Insight
          <year>2019</year>
<volume>4</volume>
<fpage>126751</fpage>
<pub-id pub-id-type="doi">10.1172/jci.insight.126751</pub-id>
<pub-id pub-id-type="pmid">30944248</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarin</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Garcia-Perez</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hermenegildo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cano</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Changes in sex ratio from fertilization to birth in assisted-reproductive-treatment cycles</article-title>
<source/>Reprod Biol Endocrinol
          <year>2014</year>
<volume>12</volume>
<fpage>56</fpage>
<pub-id pub-id-type="doi">10.1186/1477-7827-12-56</pub-id>
<pub-id pub-id-type="pmid">24957129</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kristiansen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Knudsen</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Bathum</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Naumova</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Brix</surname>
<given-names>TH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Twin study of genetic and aging effects on X chromosome inactivation</article-title>
<source/>Eur J Hum Genet
          <year>2005</year>
<volume>13</volume>
<fpage>599</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1038/sj.ejhg.5201398</pub-id>
<pub-id pub-id-type="pmid">15756296</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>